



Curriculum Vitae

Personal information Anders Bjartell

Work experience

1990-1992	Internship, Skåne University Hospital, Malmö
1992-1998	Resident in Urology, Skåne University Hospital, Malmö
1998-2004	Consultant in Urology, Skåne University Hospital, Malmö
2004-	Senior Consultant in Urology, Skåne University Hospital, Malmö
2006 -	Professor of Clinical Urology Lund University and a Senior Consultant and Head of Clinical Trial Unit at Skåne University Hospital in Malmö, Sweden

Education and training

1986	MD Lund University
1990	PhD Lund University in Medical Cell Research
1995	Associate Professor in Histology
1998	Certified Specialist in Urology Sweden
1999	Associate Professor in Urology
2000	Certified Specialist European Board of Urology (FEBU)

Additional information

Publications

PuPublications by Sept 17, 2025

WWeb of Science: 552 publications, 18055 citations

PUPubMed: 433 publications, 45 reviews <http://www.ncbi.nlm.nih.gov/pubmed/?term=bjartell>

h-iH-index: 72 (Web of science)

Original Articles in Professional Peer-Reviewed Journals

1. R. Ekman, A. **Bjartell**, E. Ekblad, F. Sundler. Immunoreactive Delta Sleep-Inducing Peptide in Pituitary Adrenocorticotropin/Alpha-Melanotropin Cells and Adrenal Medullary Cells of the Pig. *Neuroendocrinology*45:298-304. 1987.
2. A. **Bjartell** and M. Grabe. Acute urinary retention in herpes genitalis infection. *Läkartidningen* 84:3500-3501 (1987).
3. A. **Bjartell**, R. Ekman and F. Sundler. Gamma-2-MSH-like immunoreactivity in porcine pituitary and adrenal medulla. An immunochemical and immunocytochemical study. *Regul. Pept.* 6:291-309, 1987. Erratum in: *Regul Pept* 1988 Mar;20(3):272.
4. A. Fjellestad-Paulsen, P.-A. Abrahamsson, A. **Bjartell**, M. Grino, L. Grimelius, H. Hedeland and S. Falkmer. Carcinoma of the prostate with Cushing's syndrome. *Acta Endocrinol.* 119:506-516, 1988.
5. A. **Bjartell**, R. Ekman, S. Bergqvist and E. Widerlöv. Reduction of immunoreactive ACTH in

- plasma following intravenous injection of DSIP in man. *Psychoneuroendocrinology* 14:347-355, 1989.
6. A. **Bjartell**, R. Ekman, J. Hedenbro, K. Sjölund and F. Sundler. Delta Sleep-Inducing Peptide (DSIP) like immunoreactivity in gut: Co-existence with known peptide hormones. *Peptides* 10:163-170, 1989.
7. R. Ekman, A. **Bjartell**, B. Lisander and L. Edvinsson. Gamma-2-MSH Immunoreactivity in the Human Heart. *Life Science* 45:787-792, 1989.
8. A. **Bjartell**, P. Persson, A. Absood, F. Sundler and R. Håkanson. Helodermin-like peptides in noradrenaline cells of adrenal medulla. *Regul. Pept.* 26:27-34, 1989.
9. H. Ahlman, L. Åhlund, O. Nilsson, A. Dahlström, A. **Bjartell** and R. Ekman. Coexistence of delta sleep-inducing peptide and serotonin in mid-gut carcinoid tumour cells in vivo and in vitro. *Int. J. Cancer* 44, 1989.
10. A. **Bjartell**, M. Castro, R. Ekman, F. Sundler, E. Widerlöv and Y.P. Loh. Immunoreactive Delta Sleep-Inducing Peptide Secretion from Mouse Dissociated, Anterior Pituitary Cells: Regulation by Corticotropin-Releasing Factor and Arginine Vasopressin. *Neuroendocrinology* 50:564-569, 1989.
11. A. **Bjartell**, M. Fenger, R. Ekman and F. Sundler. Amidated Joining Peptide in the Human Pituitary, Gut, Adrenal Gland and Bronchial Carcinoids. Immunohistochemical and Immunochemical Evidence. *Peptides* 11:1-13, 1990.
12. A. **Bjartell**, R. Ekman and Y. P. Loh. Biosynthesis and Processing of Delta Sleep-Inducing Peptide-Like Precursors in Primary Cultures of Mouse Anterior Pituitary Cells. *Eur. J. Biochem.* 190:131-137, 1990.
13. A. **Bjartell**, R. Ekman and F. Sundler. Immunoreactive Delta Sleep-Inducing Peptide in the rat hypothalamus, pituitary and adrenal gland: Effects of adrenalectomy. *Hormone Res.* 36:52-62, 1991.
14. A. **Bjartell**, F. Sundler and R. Ekman. Extraction and immunochemical characterization of Delta Sleep-Inducing Peptide-like material from the porcine pituitary and adrenal gland. *Peptides* 12:445-454, 1991.
15. O. Nilsson, B. Wängberg, A. Wigander, K. Lundmark, A. Dahlström, H. Ahlman, A. **Bjartell** and R. Ekman. Human pheochromocytoma cells studied in culture contain large amounts of DSIP-like material. *Peptides* 12: 1077-1083, 1991.
16. G. Skagerberg, A. **Bjartell**, P.G. Vallet and Y. Charnay. Immunocytochemical demonstration of DSIP-like immunoreactivity in the hypothalamus of the rat. *Peptides* 12:1155-1159, 1991.
17. A. **Bjartell**, T. Björk, M.-T. Matikainen, P.-A. Abrahamsson, A. di Sant'Agnese and H. Lilja. Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. *Urology* 42(5): 502-510, 1993.
18. T. Björk, A. **Bjartell**, P.-A. Abrahamsson, S. Hulkko, A. di Sant'Agnese and H. Lilja. Alpha-1-antichymotrypsin production in PSA-containing cells is common in prostate cancer but rare in benign prostatic hyperplasia. *Urology* 3: 427-434, 1994.
19. J. Malm, H. Xe Hua, A. **Bjartell**, S. Li, P.-A. Abrahamsson, B. Dahlbäck. Vitamin K-dependent Protein S in Leydig Cells of Human Testis. *Biochem. J.* 302: 845-850, 1994.

20. K. Ohlsson, A. **Bjartell** and H. Lilja. Secretory leucocyte protease inhibitor in the male genital tract: PSA-induced proteolytic processing in human semen and tissue localization. *J. Androl.* 16: 64-74, 1995.
21. X. He, L. Shen, A. **Bjartell**, and B. Dahlbäck. The gene encoding vitamin K-dependent anticoagulant protein S is expressed in multiple rabbit organs as demonstrated by Northern Blotting, in situ-hybridization and immunohistochemistry. *J. Histochem. Cytochem.* 43: 85-96, 1995.
22. X. He, L. He, A. **Bjartell**, J. Malm, H. Lilja and B. Dahlbäck. The gene encoding Vitamin K-dependent anticoagulant Protein C is expressed in human male reproductive tissues. *J. Histochem. Cytochem.* 43: 563-570, 1995.
23. A. **Bjartell**, J. Malm, C. Möller, M. Gunnarsson, Å. Lundwall and H. Lilja. Distribution and tissue expression of Semenogelin I and II in man as demonstrated by in situ-hybridization and immunocytochemistry. *J. Androl.* 17(1):17-26, 1996.
24. H. Weiber, C. Lindström, H. Lilja, A. **Bjartell** and P. Fernlund. Immunohistochemical and in situ hybridization studies of beta-microseminoprotein in the human gastric mucosa. *Histochem. J.* 29: 839-845, 1997.
25. E.Th. Ruijter, G.J. Miller, T.W. Aalders, C.H. Van de Kaa, J.A. Schalken, F.M. Debruyne and the **Biomed II-MPS study group**. Rapid microwave-stimulated fixation of entire prostatectomy specimens. *J of Pathology*183(3): 369-375, 1997.
26. T. Jiborn, A. **Bjartell** and P.-A. Abrahamsson. Neuroendocrine differentiation in prostate cancer during hormonal treatment. *Urology* 51(4): 585-589, 1998.
27. P. Autzen, C.N. Robson, A. **Bjartell**, A.J. Malcolm, M.I. Johnson, D.E. Neal and F.C. Hamdy. Localization of mRNA for bone morphogenic protein-6 in skeletal metastases from prostate cancer and other common malignancies by *in situ* hybridization. *Br. J. Cancer* 78(9): 1219-23, 1998
28. G. Aumüller, M. Leonhardt, M. Janssen, L. Konrad, A. **Bjartell**, and P.-A. Abrahamsson. Neurogenic origin of human prostatic endocrine cells. *Urology* 53: 1041-1048, 1999.
29. T.J. Dorkin, M.C. Robinson, A. **Bjartell**, T. Jiborn, D.E. Neal and H.Y. Leung. Fibroblast growth factor 8 overexpression in prostate cancer is associated with decreased patient survival. *Oncogene* 18:2755-2761, 1999.
30. A. **Bjartell**, S. Laine, K. Pettersson, E. Nilsson, T. Lövgren, and H. Lilja. Time-resolved fluorescence in immunocytochemical detection of prostate-specific antigen in prostatic tissues sections. *Histochem. J.* 31: 45-52, 1999.
31. J. Malm, O. Sorensen, T. Persson, M. Frohm-Nilsson, B. Johansson, A. **Bjartell**, H. Lilja, M. Ståhle-Bäckdahl,, N. Borregaard, A. Egesten. The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal fluid at high concentration, and is attached to the spermatozoa. *Infect. Immun.* 68: 4297-4302, 2000.
32. O. Grip, J. Malm, B. Veress, A. **Bjartell**, S. Lindgren, A. Egesten. Increased presence of cells containing transforming growth factor alpha (TGF- α) in ulcerative colitis, both during active inflammation and in remission. *Eur. J. of Gastroenterol. Hepatol.* 12: 761-766, 2000.
33. A. Scorilas, A. **Bjartell**, H. Lilja, C. Moller, E.P. Diamandis. Streptavidin - Polyvinylamine Conjugates Labeled with a Europium Chelate: Applications in Immunoassay, Immunohistochemistry and Microarrays. *Clin. Chem.* 46: 1450-1455, 2000.

34. P. Siivola, K. Pettersson, T. Piironen, T. Lövgren, H. Lilja and A. **Bjartell**. Time-resolved fluorescence imaging (TRFI) for specific and quantitative immunodetection of human kallikrein 2 (hK2) and prostate-specific antigen (PSA) in prostatic tissue sections. *Urology* 56: 682-688, 2000
35. A. Paju, A. **Bjartell**, W.-M. Zhang, S. Nordling, A. Borgström, J. Hansson, U.-H. Stenman. Expression and characterization of trypsinogen produced in the human male genital tract. *Am. J. Pathol.* 157: 2011-2021, 2000.
36. V. Väisänen, H. Härmä, H. Lilja, A. **Bjartell**. Time-resolved fluorescence imaging for quantitative histochemistry – using lanthanide chelates in nanoparticles and conjugated to monoclonal antibodies. *Luminescence* 15: 389-397, 2000.
37. G. Aumüller, M. Leonhardt, H. Renneberg, B. von Rahden, A. **Bjartell** and P.-A. Abrahamsson. Semiquantitative Morphology of Human Prostatic Development and Regional Distribution of Prostatic Neuroendocrine Cells. *The Prostate* 46: 108-115, 2001.
38. [Lazou Ahren I, Bjartell A, Egesten A, Riesbeck K](#). Lipopolysaccharide-binding protein increases toll-like receptor 4-dependent activation by nontypeable Haemophilus influenzae. *J Infect Dis.* 184(7):926-30, 2001.
39. Syk I, Mangell P, **Bjartell** A, Jeppsson B. Systemic interleukin-6 response to colorectal surgery originates from the bowel. *Dig Surg.* 19(3):210-215, 2002.
40. Å. Lundwall, A. **Bjartell**, Y. Olsson, J. Malm. Human Semenogelin I and II, the predominating seminal plasma proteins are also expressed in non-genital tissues. *Mol. Human Reprod.* 8:805-810, 2002.
41. J. Hansson, A. **Bjartell**, V. Gadaleanu, N. Dizeyi, P.-A. Abrahamsson. Expression of Somatostatin Receptor Subtypes 2 and 4 in Human Benign Prostatic Hyperplasia and Prostatic Cancer. *The Prostate* 53:50-59, 2002.
42. Yu-e Cao, Å. Lundwall, V. Gadaleanu, H. Lilja, A. **Bjartell**. Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2. *Am. J. Pathol.* 161: 2053-2063, 2002.
43. N. Dizeyi, L. Konrad, A. **Bjartell**, H. Wu, V. Gadaleanu, J. Hansson, L. Helboe, P.-A. Abrahamsson. Localization and mRNA expression of Somatostatin Receptor in human prostatic tissues and prostate cancer cell lines. *Urologic Oncology* 7:91-98, 2002.
44. [Hakansson HO, Mellblom L, Johansson J, Bjartell A, Borgstrom A](#). Synthesis and localization of pancreatic secretory proteins in pancreatic acinar-like metaplasia in the distal part of the oesophagus. Pancreatic acinar metaplasia: another source of pancreatic enzymes. *Scand J Gastroenterol.* 8(1):10-13, 2003.
45. [Persson T, Monsef N, Andersson P, Bjartell A, Malm J, Calafat J, Egesten A](#). Expression of the neutrophil-activating CXC chemokine ENA-78/CXCL5 by human eosinophils *Clin Exp Allergy.* 33(4):531-7, 2003.
46. [Persson-Dajotoy T, Andersson P, Bjartell A, Calafat J, Egesten A](#). Expression and production of the CXC chemokine growth-related oncogene-alpha by human eosinophils. *J Immunol.* 170(10):5309-5316, 2003.
47. M. Albrecht, A. Mittler, B. Wilhelm, Å. Lundwall, H. Lilja, G. Aumüller, A. **Bjartell**.

Expression and Immunolocalisation of Neutral Endopeptidase in Prostate Cancer. *Eur Urol.* 44(4):415-22, 2003.

48. Y. Cao, C. Becker, A. Christensen, Å. Lundwall, H. Lilja, A. **Bjartell**. Expression of protein C inhibitor (PCI) in benign and malignant prostate tissue. *Prostate.* 57(3):196-204, 2003.

49. J.C. Liao Persson, S.Q. Li, X.Y. Wang, S. Muhlrad, A. **Bjartell**, D.J. Wolgemuth. Elevated Levels and Distinct Patterns of Expression of A-Type Cyclins and Their Associated Cyclin-Dependent Kinases in Male Germ Cell Tumors. *Int J Cancer* 108(5):654-64, 2004.

50. N. Dizeyi, A. **Bjartell**, E. Nilsson, J. Hansson, V. Gadaleanu, N. Cross, P.-A. Abrahamsson. Expression of Serotonin Receptors and Role of Serotonin in Human Prostate Cancer Tissue and Cell Lines. *Prostate* 59(3):328-36, 2004

51. H. Steiner, A.P. Berger, S. Godoy-Tundidor, A. **Bjartell**, H. Lilja, G. Bartsch, A. Hobisch, Z. Culig. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin-6. *Eur J Cancer* 40(7):1066-72, 2004.

52. T. Dajotoy, P. Andersson, A. **Bjartell**, C.G. Löfdahl, H. Tapper, A. Egesten. Human eosinophils produce the T cell attracting chemokines MIG and IP-10 upon stimulation with interferon-gamma. *J Leukocyte Biology*,76(3):685-691, 2004.

53. T. Jiborn, J. Malm, M. Abrahamsson, K.-M. Nathansson, P.-A Abrahamsson, A. **Bjartell**. Cystatin C is highly expressed in the human male reproductive system. *J Androl.* 25(4):564-572, 2004.

54. A Y Olsson, A **Bjartell**, H Lilja, Å Lundwall. Extraprostatic tissue distribution of prostate-specific antigen and human glandular kallikrein 2. *Int J Cancer.* 113(2):290-297, 2005.

55. S Lintula, J Stenman, A **Bjartell**, S Nordling, U-H Stenman. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. *The Prostate.* 63(4): 324-329, 2004.

56. A. **Bjartell**, A. Paju, W.-M. Zhang, V. Gadaleanu, J. Hansson, G. Landberg, U.-H. Stenman. Expression of Tumor associated trypsinogens (TATI-1 and TATI-2) in Prostate Cancer. *The Prostate.* 64: 29-39, 2005.

57. J. Dejmek, K. Leandersson, J. Manjer, A. **Bjartell**, S.O. Emdin, W.F. Vogel, G. Landberg, T. Andersson. Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival.. *Clin Cancer Res.* 11:520-528, 2005.

58. L Udby, A. **Bjartell**, J Malm, N Borregaard, L Kjeldsen. Characterization and Localization of Cysteine-Rich Secretory Protein 3 (CRISP-3) in the Human Male Reproductive Tract. *J Androl* 26: 333-342, 2005.

59. N Dizeyi, A **Bjartell**, P Hedlund, KA Taskén, V Gadaleanu, PA Abrahamsson. Expression of Serotonin Receptors 2B and 4 in Human Prostate Cancer Tissue and Effects of Their Antagonists on Prostate Cancer Cell Lines. *Eur Urol* 47: 895-900, 2005.

60. J. Malm, E. Andersson-Nordahl, A. **Bjartell**, Ole Sørensen, B. Frohm, M.A. Dentener, A. Egesten. Lipopolysaccharide-binding protein is produced in the epididymis and associated with spermatozoa and prostasomes. *J Reproductive Immunology* 66: 33-43, 2005.

61. L Udby, Å Lundwall, AH Johnsen, P Fernlund, C Valtonen-André, AM Blom, H Lilja, N Borregaard, L Kjeldsen, A. **Bjartell**. β -microseminoprotein binds CRISP-3 in human seminal plasma.

Biochem Biophys Res Comm. 333: 555-561, 2005.

62. B. Wegiel, A. **Bjartell**, J Ekberg, V. Gadaleanu, J. Liao Persson. An role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer. *Oncogene* 24: 6385 – 6393.

63. van Gils MP, Stenman UH, Schalken JA, Schroder FH, Lilja H, **Bjartell** A, Hamdy FC, Pettersson K, Bischoff R, Takalo H, Nilsson O, Mulders PF, Bangma CH. Innovations in Serum and Urine Markers in Prostate Cancer Current European Research in the P-Mark Project. *Eur Urol* 48: 1031-1041, 2005, 176. Epub 2005 Jul 1. (Peer-reviewed review)

64. M Grabe, A **Bjartell**, B Wullt. PROQR: A tool for quality control, epidemiological surveillance, patient follow-up and clinical research activities related to prostate cancer. *Acta Oncol* 44: 628-632, 2005.

65. M Stenman, M Ainola, L Valmu, A. **Bjartell**, G Ma, U-H Stenman, T Sorsa, R Luukkainen, Y T Konttinen. Trypsin-2 degrades human type II collagen and is expressed and activated in mesenchymally transformed rheumatoid arthritis synovitis tissue. *Am J Pathol* 167: 1119-1124, 2005.

66. K Hotakainen, A **Bjartell**, A Sankila, R Järvinen, A Paju, E Rintala, C Haglund, U-H Stenman. Differential expression of trypsinogen and tumor associated trypsin inhibitor (TATI) in bladder cancer. *Int J Oncol* 28(1):95-101, 2006

67. A Giwercman, N Dizeyi, Å Lundwall, A. **Bjartell**, YL Giwercman. Testicular cancer and molecular genetics. *Andrologia*. 2005 Dec;37(6):224-5.

68. A. **Bjartell**, R. Johansson, T. Björk, V. Gadaleanu, Å. Lundwall, H. Lilja, L. Kjeldsen, L. Udby. Immunohistochemical Detection of Cysteine-Rich Secretory Protein-3 in Tissue has Greater Diagnostic Utility for Prostate Cancer than Serum Measurements. *The Prostate* 66:591-603,2006

69. L-O Cardell, A. **Bjartell**, R Uddman, A Egesten. Topical steroids do not downregulate expression of the CXC-chemokine growth-related oncogene alpha in nasal polyps in vivo. *Acta Otolaryngologica* 126:375-380, 2006

70. **Bjartell** A. Words of wisdom. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. *Eur Urol*. 2006 Apr;49(4):758-9.

71. T Jiborn, M Abrahamson, V Gadaleanu, Å Lundwall, A. **Bjartell**. Aberrant Expression of Cystatin C in prostate cancer is associated with neuroendocrine differentiation. *Br J Urol Int*. 98:189-196, 2006.

72. CD Ciornei, H Tapper, A. **Bjartell**, NH. Sternby, M Bodelsson. Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces apoptosis in vascular smooth muscle cells. *BMC Cardiovascular Disorders* 6:49, 2006

73. Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V, Hemminki A, Stenman UH, **Bjartell** A. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. *Eur Urol*. 2007 Dec;52(6):1670-9.

74. Valtonen-André C, **Bjartell** A, Hellsten R, Lilja H, Härkönen P, Lundwall A. [A highly conserved](#)

[protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue](#). Biol Chem. 2007 Mar;388(3):289-95.

75. Monsef N, Helczynski L, Lundwall A, Pålman S; **Bjartell A**. Localization of Immunoreactive HIF-1a and HIF-2a in neuroendocrine cells of the benign and malignant prostate. Prostate. 2007 Aug 1;67(11):1219-29.

76. [Secin FP, Jiborn T, Bjartell AS, Fournier G, Salomon L, Abbou CC, Haber GP, Gill IS, Crocitto LE, Nelson RA, Cansino Alcaide JR, Martinez-Pineiro L, Cohen MS, Tuerk I, Schulman C, Gianduzzo T, Eden C, Baumgartner R, Smith JA, Entezari K, van Velthoven R, Janestschek G, Serio AM, Vickers AJ, Touijer K, Guillonneau B](#). Multi-institutional Study of Symptomatic Deep Venous Thrombosis and Pulmonary Embolism in Prostate Cancer Patients Undergoing Laparoscopic or Robot-Assisted Laparoscopic Radical Prostatectomy. Eur Urol. 2008 Jan;53(1):134-45.

77. **Bjartell A**. Words of wisdom. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Eur Urol. 2006 Apr;49(4):758-9.

78. **Bjartell AS**, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW, Udby L, Gerald WL, Vickers AJ, Lilja H, Reuter VE, Scardino PT. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res. 2007 Jul 15;13(14):4130-8.

79. Egesten A, Eliasson M, Olin AI, Erjefalt JS, **Bjartell A**, Sangfelt P, Carlson M. The proinflammatory CXC-chemokines GRO-alpha/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids. Int J Colorectal Dis. 2007 Dec;22(12):1421-7.

80. **Bjartell A**. PSA and prostate cancer screening: the challenge of the new millennium. Eur Urol. 2007 Nov;52(5):1284-6.

81. Wallström P, **Bjartell A**, Gullberg B, Olsson H, Wirfält E. A prospective study on dietary fat and incidence of prostate cancer (Malmo, Sweden). Cancer Causes Control. 2007 Dec;18(10):1107-21.

82. Malm J, Sonesson A, Hellman J, **Bjartell A**, Frohm B, Hillarp A. The Pentraxin Serum Amyloid P component is found in the male genital tract and attached to spermatozoa. Int J Androl. 2008 Sep;31(5):508-17.

83. Wegiel B, **Bjartell A**, Culig Z, Persson JL. Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer. 2008 Apr 1;122(7):1521-9.

84. Vilen ST, Nyberg P, Hukkanen M, Sutinen M, Ylipalosaari M, **Bjartell A**, Paju A, Haaparanta V,

Stenman UH, Sorsa T, Salo T. [Intracellular co-localization of trypsin-2 and matrix metalloprotease-9: possible proteolytic cascade of trypsin-2, MMP-9 and enterokinase in carcinoma.](#) Exp Cell Res. 2008 Feb 15;314(4):914-26

85. Hellsten R, Johansson M, Dahlman A, Dizeyi N, Sterner O, **Bjartell A**. Galiellalactone inhibits growth of prostate cancer xenografts and induces apoptosis of human prostate cancer cells expressing activated Stat3. Prostate. 2008 Feb 15;68(3):269-80.

86. Järås K, Ahmad Tajudin A, Ressine A, Soukka T, Marko-Varga G, **Bjartell A**, Malm J, Laurell T, Lilja H. ENSAM: Europium Nanoparticles for Signal Enhancement of Antibody Microarrays on Nanoporous Silicon. J Proteome Res. 2008 Mar;7(3):1308-14.

87. Linge HM, Collin M, Giwercman A, Malm J, **Bjartell A**, Egesten A. The antibacterial chemokine MIG/CXCL9 is constitutively expressed in epithelial cells of the male urogenital tract and is present in seminal plasma. J Interferon Cytokine Res. 2008 Mar;28(3):191-6.

88. Valta MP, Tuomela J, **Bjartell A**, Valve E, Väänänen HK, Härkönen P. FGF-8b is involved in bone metastasis of prostate cancer bone. Int J Cancer. 2008 Jul 1;123(1):22-31.

89. Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, **Bjartell A**, Abrahamsson PA, Taskén KA. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008 Jul 1;68(10):1133-42.

90. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andrén O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, **Bjartell AS**, Chinnaiyan AM. Outlier Expression of SPINK1 Defines an Aggressive Molecular Subtype of ETS Rearrangement Negative Prostate Cancer. Cancer Cell 2008. Jun;13(6):519-28. [**Bjartell and Chinnaiyan share senior authorship**]

91. Wegiel B, **Bjartell A**, Tuomela J, Dizeyi N, Tinzl M, Helczynski L, Nilsson E, Otterbein LE, Härkönen P, Persson JL. Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. J Natl Cancer Inst. 2008 Jul 16;100(14):1022-36.

92. Collin M, Linge HM, **Bjartell A**, Giwercman A, Malm J, Egesten A. Constitutive expression of the antibacterial CXC chemokine GCP-2/CXCL6 by epithelial cells of the male reproductive tract. J Reprod Immunol. 2008 Oct;79(1):37-43.

93. Yossepowitch O, **Bjartell A**, Eastham JA, Graefen M, Guillonneau BD, Karakiewicz PI, Montironi R, Montorsi F. [Positive Surgical Margins in Radical Prostatectomy: Outlining the Problem and Its Long-Term Consequences.](#) Eur Urol. 2009 Jan;55(1):87-99.

94. Jhavar S, Brewer D, Edwards S, Kote-Jarai Z, Attard G, Clark J, Flohr P, Christmas T, Thompson A, Parker M, Shepherd C, Stenman UH, Marchbank T, Playford RJ, Woodhouse C,

- Ogden C, Fisher C, Kovacs G, Corbishley C, Jameson C, Norman A, De-Bono J, **Bjartell A**, Eeles R, Cooper CS. Integration of ERG gene mapping and gene expression profiling identifies distinct categories of human prostate cancer. *BJU Int*. 2009 May;103(9):1256-69.
95. Seitz M, Shukla-Dave A, **Bjartell A**, Touijer K, Sciarra A, Bastian P, Stief C, Hricak H, Graser A. Functional Magnetic Resonance Imaging in Prostate Cancer. *Eur Urol*. 2009 Apr;55(4):801-14.
96. Bastian PJ, Carter BH, **Bjartell A**, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schröder F. [Insignificant Prostate Cancer and Active Surveillance: From Definition to Clinical Implications](#). *Eur Urol*. 2009 Jun;55(6):1321-30.
97. Gaber A, Johansson M, Stenman UH, Hotakainen K, Pontén F, Glimelius B, **Bjartell A**, Jirström K, Birgisson H. [High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer](#). *Br J Cancer*. 2009 May 19;100(10):1540-8.
98. Tomlins SA, **Bjartell A**, Chinnaiyan AM, Jenster G, Nam R, Rubin MA, Schalken JA. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. *Eur Urol*. 2009 Aug;56(2):275-86.
99. Wallström P, **Bjartell A**, Gullberg B, Olsson H, Wirfält E. A prospective study on body size, body composition, diabetes, and risk of prostate cancer. *Br J Cancer*. 2009 Jun 2;100(11):1799-805.
100. Chi KN, **Bjartell A**, Dearnley D, Saad F, Schröder FH, Sternberg C, Tombal B, Visakorpi T. [Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets](#). *Eur Urol*. 2009 Oct;56(4):594-605.
101. Tassidis H, Brokken LJ, Jirström K, Ehrnström R, Pontén F, Ulmert D, **Bjartell A**, Härkönen P, Wingren AG. Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer. *Int J Cancer*. 2010 May 15;126(10):2296-307.
102. Dizeyi N, Hedlund P, **Bjartell A**, Tinzl M, Austild-Taskén K, Abrahamsson PA. Serotonin activates MAP Kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. *Urol Oncol*. 2011 Jul-Aug;29(4):436-45.
103. Wegiel B, Jiborn T, Abrahamson M, Helczynski L, Otterbein L, Persson JL, **Bjartell A**. Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. *PLoS One*. 2009 Nov 23;4(11):e7953.
104. Murphy DG, **Bjartell A**, Ficarra V, Graefen M, Haese A, Montironi R, Montorsi F, Moul JW, Novara G, Sauter G, Sulser T, van der Poel H. [Downsides of Robot-assisted Laparoscopic Radical Prostatectomy: Limitations and Complications](#). *Eur Urol*. 2010 May;57(5):735-46.
105. Uusijärvi H, Nilsson LE, **Bjartell A**, Mattsson S. Biokinetics of 18F-choline studied in four prostate cancer patients. *Radiat Prot Dosimetry*. 139(1-3):240-4, 2010
106. Klein RJ, Halldén C, Cronin AM, Ploner A, Wiklund F, **Bjartell AS**, Stattin P, Xu J, Scardino PT, Offit K, Vickers AJ, Grönberg H, Lilja H. Blood biomarker levels to aid discovery of cancer-related single nucleotide polymorphisms: kallikreins and prostate cancer. *Cancer Prev Res (Phila Pa)*. 3(5):611-9, 2010
107. Wegiel B, Evans S, Hellsten R, Otterbein LE, **Bjartell A**, Persson JL. Molecular pathways in the progression of hormone-independent and metastatic prostate cancer. *Curr Cancer Drug Targets* 10(4):392-401, 2010

108. Ruhayel R, Giwercman A, Ulmert D, Rylander L, **Bjartell A**, Manjer J, Berglund G, Giwercman Y. Male infertility and prostate cancer: a nested case-control study. *Cancer Causes Control*. 21(10):1635-43, 2010
109. Dahlman A, Edsjö A, Halldén C, Persson JL, Lilja H, Gerald W, **Bjartell A**. Effect of androgen deprivation on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3. *Prostate Cancer Prostatic Dis* 13(4):369-75, 2010
110. Schwenk JM, Igel U, Neiman M, Lagnen H, Becker C, **Bjartell A**, Pontén F, Wiklund F, Grönberg H, Nilsson P, Uhlén M. Towards next generation plasma profiling via heat-induced epitope retrieval and array-based assays. *Mol Cell Proteomics*. 9(11):2497-507, 2010
111. Vickers AJ, Cronin AM, Björk T, Manjer J, Nilsson PM, Dahlin A, **Bjartell A**, Scardino PT, Ulmert D, Lilja H. Prostate-specific antigen level at age 60 and death or metastasis from prostate cancer. *BMJ*. 14;341:c4521, 2010
112. Petterson T, Jendholm J, Månsson A, **Bjartell A**, Riesbeck K, Cardell LO. [Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and Toll-like receptors.](#) *J Leukoc Biol.*;89(2):177-87, 2011
113. Gaber A, Nodin B, Hotakainen K, Nilsson E, Stenman UH, **Bjartell A**, Birgisson H, Jirström K. [Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients.](#) *BMC Cancer*. 17;10:498, 2010
114. Secin FP, Savage C, Abbou A, de La Taille A, Salomon L, Rassweiler J, Hruza M, Rozet F, Cathelineau X, Janetschek G, Nassar F, Turk I, Vanni AJ, Gill IS, Koenig P, Kaouk JH, Martinez-Pineiro L, Pansadorov, Emiliozzi P, **Bjartell A**, Jiborn T, Eden C, Richards AJ, Van Velthoven R, Stolzenburg J-U, Rabenalt R, Su L-M, Pavlovich CP, Levinson AW, Touijer KA, Vickers A, Guillonneau B. The learning curve for laparoscopic radical prostatectomy: an international multicenter study. *J Urol*. 184(6):2291-6, 2010
115. Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, **Bjartell AS**, Scardino PT, Ulmert D, Vickers AJ. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. *Cancer* 15;117(6):1210-9, 2011
116. Nyberg M, Ulmert D, Lindgren A, Lindström U, Abrahamsson PA, **Bjartell A**. PCA3 as a diagnostic marker for prostate cancer: A validation study on a Swedish patient population. *Scand J Urol Nephrol*. 44(6):378-83, 2010
118. Schaar V, deVries S, Perez-Vidakovics M, Bootsma H, Larsson L, Hermans P, **Bjartell A**, Mörgelin M, Riesbeck K. Multicomponent Moraxella Catarrhalis Outer Membrane Vesicles Induce an Inflammatory Response and are Internalized by Human Epithelial Cells. *Cell Microbiol*. 13(3):432-49, 2011
119. Vickers A, Gupta A, Savage CJ, Pettersson K, Dahlin A, **Bjartell A**, Manjer J, Scardino PT, Ulmert D, Lilja H. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. *Cancer Epidemiol Biomarkers Prev*. 20(2):255-61, 2011
120. Dahlman A, Rexhepaj E, Brennan DJ, Gallagher WM, Schlomm T, Jirström K, **Bjartell A**. Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. *Mod Pathol*. 24(5):708-19, 2011

122. Östling P, Leivonen S-K, Aakula A, Kohonen P, Mäkelä R, Hagman Z, Edsjö A, Kangaspeska S, Edgren H, Nicorici D, **Bjartell A**, Ceder Y, Perälä M, Kallioniemi O. Systematic analysis of microRNAs targeting Androgen Receptor in prostate cancer cells. *Cancer Res.* 71(5):1956-67, 2011.
123. Hagman Z, Larne O, Edsjö A, **Bjartell A**, Ehrnström RA, Ulmert D, Lilja H, Ceder Y. miR-34c is down regulated in prostate cancer and exerts tumor suppressive functions. *Int J Cancer.* 15;127(12):2768-76, 2010
125. Hoogland AM, Dahlman A, Vissers KJ, Wolters T, Schröder FH, Roobol MJ, **Bjartell AS**, van Leenders G JLH. Validation of CRISP-3 and β -MSP prognostic value on prostate cancer needle biopsies in men treated by prostatectomy. *BJU Int.* 108(8):1356-62, 2011
133. Magnusson K, de Wit M, Brennan DJ, Johnson LB, McGee SF, Lundberg E, Naicker K, Klinger R, Kampf C, Asplund A, Wester K, Gry M, **Bjartell A**, Gallagher WM, Rexhepaj E, Kilpinen S, Kallioniemi OP, Belt E, Goos J, Meijer G, Birgisson H, Glimelius B, Borrebaeck CAK, Navani S, Uhlén M, PhD5, O'Connor DP, Jirström K, Pontén F. SATB2 in combination with Cytokeratin 20 identifies over 95% of all colorectal carcinomas. *Am J Surg Pathol.* 35(7):937-48, 2011
135. Patschan O, Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Lotan Y, Hotakainen K, Stenman UH, **Bjartell A**. Correlation of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the bladder. *World J Urol.* 30(6):785-94, 2012
136. Hellsten R, Johansson M, Sterner O, **Bjartell A**. Galiellalactone decreases the population of stem cell-like ALDH-positive prostate cancer cells. *PLoS One.* 6(7):e22118, 2011
137. Gaber A, Stene C, Hotakainen K, Nodin B, Palmquist I, **Bjartell A**, Stenman UH, Jeppsson B, Johnson L, Jirström K. Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients. *Radiat Oncol.* 24;6:100, 2011
139. Auprich M, **Bjartell A**, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H. Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer. *Eur Urol.* 60(5):1045-54, 2011
140. Jonsson L, Gaber A, Ulmert D, Uhlén M, **Bjartell A**, Jirström K. High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression. *Diagn Pathol.* 6:91, 2011
141. Syed Khaja AS, Helczynski L, Edsjö A, Ehrnström R, Lindgren A, Ulmert D, Andersson T*, **Bjartell A***. Elevated levels of Wnt-5a protein in Prostate cancer is associated with better outcome. *PLoS One.* 6(10):e26539, 2011 (*these authors contributed equally to this work)
142. Klein RJ, Gupta A, Savage CJ, Vickers AJ, Dahlin A, **Bjartell A**, Manjer J, Scardino PT, Ulmert D, Wallström P, Hallden C, Lilja H. Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. *Eur Urol.* 61(3):471-7, 2012
143. Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson PA, Björk T, Gerdtsson A, **Bjartell A**, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, Richter J, Sadik M, Morris MJ, Scher HI, Sjöstrand K, Yu A, Suurküla M, Edenbrandt L, Larson SM. [A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients](#)

[Using the Bone Scan Index.](#) *Eur Urol.* 62(1):78-84, 2012

145. Evans-Axelsson S, Ulmert D, Örbom A, Peterson P, Nilsson O, Wennerberg J, Strand J, Wingårdh K, Olsson T, Hagman Z, Tolmachev V, **Bjartell A**, Lilja H, Strand SE. Targeting free prostate specific antigen (fPSA) for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free PSA alone. *Cancer Biother Radiopharm.* 27(4):243-51, 2012.
146. Giussani A, Janzen T, Uusijärvi-Lizana H, Tavola F, Zankl M, Sydoff M, **Bjartell A**, Leide-Svegborn S, Söderberg M, Mattsson S, Hoeschen C, Cantone MC. A compartmental model for biokinetics and dosimetry of ¹⁸F-choline in prostate cancer patients. *J Nucl Med* 53(6):985-93, 2012
147. Ahlqvist K, Saamarthy K, Syed Khaja AS, **Bjartell A**, Massoumi R. Expression of Id proteins are regulated by the Bcl-3 proto-oncogene in prostate cancer. *Oncogene.* 32(12): 1601-8, 2013
150. Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, **Bjartell A**, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ. [Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study.](#) *Eur Urol.* 63(4): 597-603, 2013
151. Rohrmann S, Linseisen J, Allen N, Bueno-de-Mesquita HB, Johnsen NF, Tjønneland A, Overvad K, Kaaks R, Teucher B, Boeing H, Pischon T, Lagiou P, Trichopoulou A, Trichopoulos D, Palli D, Krogh V, Tumino R, Ricceri F, Argüelles Suárez MV, Agudo A, Sánchez MJ, Chirlaque MD, Barricarte A, Larrañaga N, Boshuizen H, van Kranen HJ, Stattin P, Johansson M, **Bjartell A**, Ulmert D, Khaw KT, Wareham NJ, Ferrari P, Romieu I, Gunter MJ, Riboli E, Key TJ. [Smoking and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition.](#) *Br J Cancer.* 108(3):708-14, 2013
152. Larne O, Martens-Uzunova E, Hagman Z, Edsjö A, Lippolis G, Vredenburg-van den Berg MS, **Bjartell A**, Jenster G, Ceder Y. miQ – a novel microRNA based diagnostic and prognostic tool for prostate cancer. *Int J Cancer.* 132(12):2867-75, 2013
153. Tassidis H, Brokken LJS, Jirström K, **Bjartell A**, Ulmert D, Härkönen P, Gjörlöf Wingren A. Low expression of SHP-2 is associated with less favorable prostate cancer outcomes. *Tumour Biol.* 34(2):637-42, 2013
154. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttman H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efsthathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; **COU-AA-302 Investigators.** [Abiraterone in metastatic prostate cancer without previous chemotherapy.](#) *N Engl J Med.* 368(2):138-48, 2013
155. Syed Khaja AS, Egevad L, Helczynski L, Wiklund P, Andersson T, **Bjartell A**. Emphasizing the Role of Wnt5a Protein Expression to Predict Favorable Outcome after Radical Prostatectomy in Patients with Low-grade Prostate Cancer. *Cancer Medicine* 1(1):96-104, 2012
156. Nordin SL, Andersson C, Bjermer L, **Bjartell A**, Mörgelin M, Egesten A. [Midkine Is Part of the Antibacterial Activity Released at the Surface of Differentiated Bronchial Epithelial Cells.](#) *J Innate Immun.* 5(5):519-30, 2013
157. Lippolis G, Edsjö A, Stenman UH, **Bjartell A**. A high-density tissue microarray from localized

prostate cancer patients reveals ERG and TATI exclusivity in tumor cells. *Prostate Cancer Prostatic Dis.* 16(2):145-50, 2013

158. Hagman Z, Hafliðadóttir BS, Ceder J, Larne O, Edsjö A, **Bjartell A**, Lilja H, Ceder Y. miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. *Br J Cancer.* 108(8):1668-76, 2013

159. Vickers AJ, Ulmert D, Sjöberg D, Savage CJ, Björk T, Gerdtsson A, Manjer J, Nilsson PM, Dahlin A, **Bjartell A**, Scardino PT, Lilja H. A strategy for prostate cancer detection based on the relationship between prostate-specific antigen at age 40 – 55 and long-term risk of metastasis. *BMJ.* 46:f2023, 2013

164. Nordin SL, Jovic S, Kurut A, Andersson C, Gela A, **Bjartell A**, Mörgelin M, Olin AI, Lund M, Egesten A. [High Expression of Midkine in the Airways of Patients with Cystic Fibrosis.](#) *Am J Respir Cell Mol Biol.* 49(6):935-42, 2013

165. Lindahl P, Säll T, **Bjartell A**, Johansson AM, Lilja H, Halldén C. [Copy number variants in the kallikrein gene cluster.](#) *PLoS One.* 22;8(7):e69097, 2013

166. Persson J, Wilderäng U, Jiborn T, Wiklund PN, Damber JE, Hugosson J, Steineck G, Haglind E, **Bjartell A**. [Interobserver variability in the pathological assessment of radical prostatectomy specimens: Findings of the Laparoscopic Prostatectomy Robot Open \(LAPPRO\) study.](#) *Scand J Urol.* 48(2):160-7, 2013

167. Hagman Z, Hafliðadóttir BS, Ansari M, Persson M, **Bjartell A**, Edsjö A, Ceder Y. The tumor suppressor miR-34c directly targets MET in prostate cancer cells. *Br J Cancer.* 109(5):1271-8, 2013

168. Hafliðadóttir BS, Larne O, Martin M, Persson M, Edsjö A, **Bjartell A**, Ceder Y. [Upregulation of miR-96 Enhances Cellular Proliferation of Prostate Cancer Cells through FOXO1.](#) *PLoS One* 8(8):e72400, 2013

169. Lippolis G, Edsjö A, Helczynski L, **Bjartell A**, Overgaard N-C. Automated registration of multi-modality microscopy images for integrative analysis of prostate tissue sections. *BMC Cancer.* 13(1):408, 2013

170. Wegiel B, Gallo D, Czismadia E, Harris C, Belcher J, Vercellotti GM, Penacho N, Seth P, Sukhatme V, Ahmed A, Helczynski L, **Bjartell A**, Persson JL, Otterbein LE. Carbon Monoxide Induces Metabolic Exhaustion to Inhibit Tumor Growth. *Cancer Res.* 73(23):7009-21, 2013

171. Svensson C, Ceder J, Iglesias-Gato D, Chuan YC, Pang ST, **Bjartell A**, Martinez RM, Bott L, Helczynski L, Ulmert D, Wang Y, Niu Y, Collins C, Flores-Morales A. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. *Nucleic Acids Res.* 42(2):999-1015, 2014

172. Drake I, Sonestedt E, Gullberg B, **Bjartell A**, Olsson H, Adlercreutz H, Tikkanen MJ, Wirfält E, Wallström P. Plasma alkylresorcinol metabolites as biomarkers for whole-grain intake and their association with prostate cancer: a Swedish nested case-control study. *Cancer Epidemiol Biomarkers Prev.* 23(1):73-83, 2014

173. Väänänen R-M, Lilja H, Kauko L, Helo P, Cronin AM, Cicerks AJ, Nurmi M, Alanen K, **Bjartell A**, Pettersson K. Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3 and SPINK1 in histologically benign tissue from cancerous and noncancerous prostatectomy specimens. *Urology.* 83(2):511.e1-7, 2014

174. Pérez M, Collado JA, Limones CG, Hellsten R, García V, Johansson M, Sterner O, **Bjartell A**, Calzado MA, Muñoz E. The fungus metabolite Galiellalactone inhibits HIV-1 replication by interfering

with the nuclear import of NF- κ B. *Chem Biol Interact.* 5;214:69-76, 2014

175. Don-Doncow N, Escobar Z, Johansson M, Kjellström S, Garcia V, Munoz E, Sterner O, **Bjartell A**, Hellsten R. Galiellalactone is a direct inhibitor of STAT3 in prostate cancer cells. *J Biol Chem.* 289(23):15969-78, 2014

176. Selli C, **Bjartell A**, Burgos J, Somerville M, Palacio JM, Benjamin L, Black L, Castro R. Burden of illness in prostate cancer patients with a low-to-moderate risk of progression: a one-year, pan-European observational study. *Prostate Cancer* 2014:472949, 2014

177. Qundos U, Johannesson H, Fredolini C, O'Hurley G, Branca R, Uhlén M, Wiklund F, **Bjartell A**, Nilsson P, Schwenk JM. Plasma levels of carnosine dipeptidase 1 decrease in prostate cancer patients with lymph node metastasis. *Translational Proteomics* 2:14-24, 2014

178. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; **PREVAIL Investigators**. [Enzalutamide in metastatic prostate cancer before chemotherapy](#). *N Engl J Med.* 371(5):424-33, 2014

179. Drake I, Wallström P, Hindy G, Ericson U, Gullberg B, **Bjartell A**, Sonestedt E, Ohru-Melander M, Wirfält E. Associations between *TCF7L2* risk variant, incident type 2 diabetes and lifestyle factors and prospective risk of prostate cancer. *Prostate.* 74(12):1161-70, 2014

180. Evans Axelsson S, Vilhelmsson Timmermand O, Welinder C, Strand SE, Tran TA, Jansson B, **Bjartell A**. Preclinical evaluation of ¹¹¹In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancer. *Am J Nucl Med Mol Imaging.* 4(4):311-23, 2014.

181. Bentmar Holgersson M, Giwercman A, **Bjartell A**, Wu FC, Huhtaniemi IT, O'Neill TW, Pendleton N, Vanderschueren D, Lean ME, Han TS, Finn JD, Kula K, Forti G, Casanueva FF, Bartfai G, Punab M, Lundberg Giwercman Y. [Androgen receptor polymorphism dependent variation in prostate specific antigen concentrations of European men](#). *Cancer Epidemiol Biomarkers Prev.* 2014 Oct;23(10):2048-56.

182. Tyritzis SI, Wallerstedt A, Steineck G, Nyberg T, Hugosson J, **Bjartell A**, Wilderäng U, Thorsteinsdottir T, Carlsson S, Stranne J, Haglind E, Wiklund NP; the LAPPRO steering committee. Thromboembolic complications in 3544 patients undergoing radical prostatectomy with or without lymph node dissection. *J Urol.* 2015 Jan;193(1):117-25.

183. Nordström M, Wingren C, Rose C, **Bjartell A**, Becker C, Lilja H and Borrebaeck CA. Identification of plasma protein profiles associated with risk groups of prostate cancer patients. *Proteomics Clin Appl.* 2014 Dec;8(11-12):951-62.

184. Wallerstedt A, Tyritzis SI, Thorsteinsdottir T, Carlsson S, Stranne J, Gustafsson O, Hugosson J, **Bjartell A**, Wilderäng U, Wiklund PN, Steineck G, Haglind E on behalf of the LAPPRO steering committee. Short-Term Results after Robot-Assisted Laparoscopic Radical Prostatectomy Compared to Open Radical Prostatectomy. *Eur Urol.* 2015 Apr;67(4):660-70.

185. Reza M, **Bjartell A**, Ohlsson M, Kaboteh R, Wollmer P, Edenbrandt L, Trägårdh E. Bone Scan Index as a Prognostic Imaging Biomarker During Androgen Deprivation Therapy. *EJNMMI Res.* 2014 Oct 17;4:58.

186. Steineck G, **Bjartell A**, Hugosson J, Axén E, Carlsson S, Stranne J, Wallerstedt A, Persson J, Wilderäng U, Thorsteinsdottir T, Gustafsson O, Lagerkvist M, Jiborn T, Haglind E, Wiklund P; on

behalf of the LAPPRO steering committee. Degree of Preservation of the Neurovascular Bundles During Radical Prostatectomy and Urinary Continence One Year after Surgery. *Eur Urol.* Eur Urol. 2015 Mar;67(3):559-68.

187. Larne O, Östling P, Hafliðadóttir BS, Hagman Z, Aakula A, Kohonen P, Kallioniemi O, Edsjö A, **Bjartell** A, Lilja H, Lundwall Å, Ceder Y. [miR-183 in Prostate Cancer Cells Positively Regulates Synthesis and Serum Levels of Prostate-specific Antigen.](#) *Eur Urol.* 2015 Oct;68(4):581-8.

188. Vilhelmsson-Timmermand O, Santos E, Thorek DL, Evans-Axelsson S, **Bjartell** A, Lilja H, Larson SM, Strand SE, Tran TA, Ulmert D. [Radiolabeled antibodies in prostate cancer: A case study showing the effect of host immunity on antibody bio-distribution.](#) *Nucl Med Biol* 2015 Apr;42(4):375-80.

189. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; **COU-AA-302 Investigators.** Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol.* 2015 Feb;16(2):152-60

190. Haglind E, Carlsson S, Stranne J, Wallerstedt A, Wilderäng U, Thorsteinsdóttir T, Lagerkvist M, Damber JE, **Bjartell** A, Hugosson J, Wiklund PN, Steineck G on behalf of the LAPPRO steering committee. Urinary Incontinence and Erectile Function after Robotic versus Open Radical Prostatectomy: A Prospective, Controlled Non-Randomized Trial (LAPPRO). *Eur Urol.* 2015 Aug;68(2):216-25.

191. Gerdtsson A, Poon BY, Thorek DLJ, Mucci LA, Evans MJ, Scardino PT, Abrahamsson PA, Nilsson P, Manjer J, **Bjartell** A, Malm J, Vickers A, Freedland SJ, Lilja H, Ulmert D. Anthropometric measures at multiple times throughout life and prostate cancer diagnosis, metastasis and death. *Eur Urol* 2015 Dec;68(6):1076-82.

192. Larne O, Hagman Z, Lilja H, **Bjartell** A, Edsjö A, Ceder Y. [miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis.](#) *Carcinogenesis.* 2015 Aug;36(8):858-66..

193. Braun K, Sjöberg D, Vickers A, Phil D, Lilja H, **Bjartell** A. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. *Eur Urol.* 2016 Mar;69(3):505-11.

194. van der Poel H, Klotz L, Andriole G, Azzouzi AR, **Bjartell** A, Cussenot O, Hamdy F, Graefen M, Palma P, Rivera AR, Stief C. Role of focal therapy in low- and intermediate risk prostate cancers. *World J Urol.* 2015 Jul;33(7):907-16.

195. Timmermand OV, Ulmert D, Evans-Axelsson S, Pettersson K, **Bjartell** A, Lilja H, Strand SE, Tran TA. Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6. *EJNMMI Res.* 2014 Dec;4(1):51.

196. Canesin G, Evans-Axelsson S, Hellsten R, Sterner O, Krzyzanowska A, Andersson T, **Bjartell** A. The STAT3 inhibitor galiellalactone effectively reduces tumor growth and metastatic spread in an orthotopic xenograft mouse model of prostate cancer. *Eur Urol.* 2016 Mar;69(3):400-4.

197. O'Hurley G, Busch C, Fagerberg L, Hallström BM, Stadler C, Tolf A, Lundberg E, Jirström K, **Bjartell A**, Gallagher WM, Uhlén M, Pontén F. Analysis of the human prostate-specific proteome defined by transcriptomics and antibody-based profiling identifies TMEM79 and ACOXL as two putative, diagnostic markers in prostate cancer. *PLoS One*. 2015 Aug 3;10(8):e0133449.
198. Prencipe M, O'Neill A, O'Hurley G, Nguyen LK, Fabre A, **Bjartell A**, Gallagher WM, Morrissey C, Kay EW, Watson RW. Relationship between Serum Response Factor and Androgen Receptor in prostate cancer. *Prostate*. 2015 Nov;75(15):1704-17.
198. Anand A, Morris MJ, Kaboteh R, Båth L, Sadik M, Gjertsson P, Lomsky M, Edenbrandt L, Minarik D, **Bjartell A**. Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer. *J Nucl Med*. 2016 Jan;57(1):41-5.
199. Chowdhury S, Birtle A, **Bjartell A**, Costa L, Feyerabend S, Galli L, Lumen N, Kalinka-Warzocha E, Maroto P, Matveev V, Paiss T, Spaeth D, Dearden L, Klumper E, Thingstad T, Wapenaar R, Lee E. The Prostate Cancer Registry: Analysis of Medical Resource Utilisation (Mru) in An International, Prospective, Observational Study of Men with Metastatic Castration-Resistant Prostate Cancer (Mcrpc). *Value Health*. 2015 Nov;18(7):A482
200. Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, **Bjartell A**, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA. Low β 2-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism. *Oncotarget*. 2016 Jan 12;7(2):1878-94.
201. Iglesias-Gato D, Wikström P, Tyanova S, Lavalley C, Thysell E, Carlsson J, Hägglöf C, Cox J, Andrén O, Stattin P, Egevad L, Widmark A, **Bjartell A**, Collins CC, Bergh A, Geiger T, Mann M, Flores-Morales A. The Proteome of Primary Prostate Cancer. *Eur Urol*. 2016 May;69(5):942-52.
202. Carlsson S, Jäderling F, Wallerstedt A, Nyberg T, Stranne J, Thorsteinsdottir T, Carlsson SV, Bjartell A, Hugosson J, Haglind E, Steineck G. Oncologic and functional outcomes one year after radical prostatectomy for very low risk prostate cancer. Results from the prospective LAPPRO trial. *BJU Int*. 2016 Aug;118(2):205-12.
203. Alinezhad S, Väänänen RM, Ochoa NT, Vertosick EA, **Bjartell A**, Boström PJ, Taimen P, Pettersson K. Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate. *BMC Urol*. 2016 Feb 29;16:10.
204. Anand A, Morris MJ, Larson SM, Minarik D, Josefsson A, Helgstrand JT, Oturai PS, Edenbrandt L, Røder MA, **Bjartell A**. Automated Bone Scan Index as a Quantitative Imaging Biomarker in Metastatic Castration Resistant Prostate Cancer Patients being treated with Enzalutamide. *EJNMMI Res* 2016 Dec;6(1):23.
205. Jäderling F, Nyberg T, Blomqvist L, **Bjartell A**, Steineck G, Carlsson S. Accurate prediction tools in prostate cancer require consistent assessment of included variables. *Scand J Urol*. 2016 Aug;50(4):260-6.
206. Krzyzanowska A, Lippolis G, Peltola M, Pettersson K, Helzcynski L, Anand A, Lilja H, **Bjartell A**. Quantitative Time Resolved Fluorescence Imaging of Androgen Receptor and Prostate Specific Antigen in Prostate Tissue Sections. *J Histochem Cytochem* 2016 May;64(5):311-22.

207. Escobar Z, **Bjartell A**, Canesin G, Evans Axelsson S, Sterner O, Hellsten R, Johansson M. Preclinical characterization of 3 β -(*N*-acetyl L-cysteine methyl ester)-2 α ,3-dihydrogaliellalactone (GPA512), a prodrug of a direct STAT3 inhibitor for the treatment of prostate cancer. *J Med Chem* 2016 May 26;59(10):4551-62.
208. **Bjartell A**, Bottai M, Persson J, Bratt O, Damber JE, Stattin P, Akre O. [Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort](#). *Scand J Urol*. 2016 Aug; 50(4):255-9.
209. Alinezhad S, Väänänen RM, Mattsson J, Li Y, Tallgrén T, Tong Ochoa N, **Bjartell A**, Åkerfelt M, Taimen P, Boström PJ, Pettersson K, Nees M. [Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies](#). *PLoS One*. 2016 May 19;11(5):e0155901.
210. Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, **Bjartell A**, Eri LM, Berge V, Svindland A, Taskén KA. [PBX3 is a putative biomarker of aggressive prostate cancer](#). *Int J Cancer*. 2016 Oct 15;139(8):1810-20.
211. Lundgren S, Warfvinge CF, Elebro J, Heby M, Nodin B, Krzyzanowska A, **Bjartell A**, Leandersson K, Eberhard J, Jirstrom K. [The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment](#). *PLoS One*. 2016 Jun 8;11(6):e0156497.
212. Don-Doncow N, Marginean F, Coleman I, Nelson PS, Ehrnström R, Krzyzanowska A, Morrissey C, Hellsten R, **Bjartell A**. Expression of pSTAT3 in Prostate Cancer Metastases. *Eur Urol*. 2017 Mar; 71(3):313-316.
213. Anand A, Morris MJ, Kaboteh R, Reza M, Trägårdh E, Matsunaga N, Edenbrandt L, **Bjartell A**, Larson SM Minarik D. A Pre-Analytical Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility due to the Procedural Variabilities of Bone Scan Image Acquisition. *J Nucl Med*. 2016 Dec; 57(12):1865-1871.
214. Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, **Bjartell AS**, Borre M, Mulders P, Tammela T, Parli T, Sari S, van Os S, Theeuwes A, Tombal B. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL study. *Eur Urol*. 2017 Feb; 71(2):151-154.
215. Derogar M, Dahlstrand H, Carlsson S, **Bjartell A**, Hugosson J, Axén E, Johansson E, Lagerkvist M, Nyberg T, Stranne J, Thorsteinsdottir T, Wallerstedt A, Haglind E, Wiklund P, Steineck G; LAPPRO steering committee. [Preparedness for side effects and bother in symptomatic men after radical prostatectomy in a prospective, non-randomized trial, LAPPRO](#). *Acta Oncol*. 2016 Dec; 55(12):1467-1476.
216. Mulvaney EP, Shilling C, Eivers SB, Perry AS, **Bjartell A**, Kay EW, Watson RW, Kinsella BT. [Expression of the TP \$\alpha\$ and TP \$\beta\$ isoforms of the thromboxane prostanoid receptor \(TP\) in prostate cancer: clinical significance and diagnostic potential](#). *Oncotarget*. 2016 Nov 8;7(45):73171-73187
217. Vickers A, Vertosick EA, Sjoberg DD, Roobol MJ, Hamdy F, Neal D, **Bjartell A**, Hugosson J, Donovan JL, Villers A, Zappala S, Lilja H. [Properties of the four kallikrein panel outside the diagnostic grey zone: meta-analysis of patients with positive digital rectal exam or prostate-specific antigen 10 ng / mL and above](#). *J Urol*. 2017 Mar;197(3 Pt 1):607-613.

218. Pin E, Henjes F, Hong MG, Wiklund F, Magnusson P, **Bjartell** A, Uhlén M, Nilsson P, Schwenk JM. [Identification Of A Novel Autoimmune Peptide Epitope Of Prostein In Prostate Cancer.](#) *J Proteome Res.* 2017 Jan 6;16(1):204-216.
219. Bentmar Holgersson M, Ruhayel Y, Karlsson M, Giwercman A, **Bjartell** A, Ohlsson C, Mellström D, Ljunggren Ö, Haghsheno MA, Damber JE, Lundberg Giwercman Y. [Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele.](#) *Cancer Causes Control.* 2017 Feb 7. PMID:28176139
220. Josefsson A, Linder A, Flondell Site D, Canesin G, Stiehm A, Anand A, **Bjartell** A, Damber JE, Welén K. [Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.](#) *Prostate.* 2017 Jun;77(8):849-858
221. Stinesen Kollberg K, Wilderäng U, Thorsteinsdottir T, Hugosson J, Wiklund P, **Bjartell** A, Carlsson S, Stranne J, Haglind E, Steineck G. How badly did it hit? Self-assessed emotional shock upon prostate cancer diagnosis and psychological well-being: a follow-up at 3, 12, and 24 months after surgery. *Acta Oncol* 2017 Jul;56(7):984-990.
222. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; **LATITUDE Investigators.** [Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.](#) *N Engl J Med.* 2017 Jul 27;377(4):352-360.
223. Solarić M, **Bjartell** A, Thyroff-Friesinger U, Meani D. [Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation.](#) *Ther Adv Urol.* 2017 Apr 18;9(6):127-136. Erratum in: *Ther Adv Urol.* 2017 Jun 05;9(7):191.
224. Drake I, Gullberg B, Sonestedt A, Stocks T, **Bjartell** A, Olsson H, Wirfält E, Wallström P, Orho-Melander M. Type 2 diabetes, adiposity, and cancer morbidity and mortality risk taking into account competing risk of noncancer deaths in a prospective cohort setting. *Int J Cancer.* 2017 Sep 15;141(6):1170-1180.
225. Bock D, Angenete E, **Bjartell** A, Carlsson S, Steineck G, Stranne J, Thorsteinsdottir T, Wiklund P, Haglind E. [Habits and self-assessed quality of life, negative intrusive thoughts and depressed mood in patients with prostate cancer: a longitudinal study.](#) *Scand J Urol.* 2017 Oct;51(5):353-359.
226. Kollberg KS, Wilderäng U, Thorsteinsdottir T, Hugosson J, Wiklund P, **Bjartell** A, Carlsson S, Stranne J, Haglind E, Steineck G. [Psychological Well-being and Private and Professional Psychosocial Support After Prostate Cancer Surgery: A Follow-up at 3, 12, and 24 Months After Surgery.](#) *Eur Urol Focus.* 2016 Oct;2(4):418-425.
227. Reza M, Ohlsson M, Kaboteh R, Anand A, Franck-Lissbrant I, Damber J-E, Widmark A, Thellenberg-Karlsson C, Budeaus L, Eichenauer T, Wollmer P, Edenbrandt L, Trägårdh E, **Bjartell** A. Bone scan index as an imaging biomarker in mCRPC: a multicentre study based on patients treated with abiraterone acetate (Zytiga™) in clinical practice. *Eur Urol Focus.* 2016 Dec;2(5):540-546.
228. Reza M, Jones R, Aspegren J, Massard C, Mattila L, Mustonen LMVJ, Wollmer P, Trägårdh E, Bondesson E, Edenbrandt L, Fizazi K, **Bjartell** A. Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study. *Eur Urol Focus* 2016 Dec;2(5):547-552.
229. Sooriakumaran P, Pini G, Nyberg T, Derogar M, Carlsson S, Stranne J, **Bjartell** A, Hugosson J,

Steineck G, Wiklund PN. [Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy: Results from the LAParoscopic Prostatectomy Robot Open Trial.](#) *Eur Urol.* 2018 Apr;73(4):618-627

230. Wallström P, Drake I, Sonestedt E, Gullberg B, **Bjartell A**, Olsson H, Adlercreutz H, Tikkanen MJ, Wirfält E. [Plasma enterolactone and risk of prostate cancer in middle-aged Swedish men.](#) *Eur J Nutr.* 2017 Sep 7. doi: 10.1007/s00394-017-1530-z. [Epub ahead of print]

231. Canesin G, Evans-Axelsson S, Hellsten R, Krzyzanowska A, Prasad CP, **Bjartell A**, Andersson T. [Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.](#) *PLoS One.* 2017 Sep 8;12(9):e0184418. doi: 10.1371/journal.pone.0184418. eCollection 2017.

232. Stinesen Kollberg K, Thorsteinsdottir T, Wilderäng U, Hugosson J, Wiklund P, **Bjartell A**, Carlsson S, Stranne J, Haglind E, Steineck G. [Social constraints and psychological well-being after prostate cancer: A follow-up at 12 and 24 months after surgery.](#) *Psychooncology.* 2018 Feb;27(2):668-675.

233. Englund E, Canesin G, Papadakos CS, Vishnu N, Persson E, Reitsma B, Anand A, Jacobsson L, Helczynski L, Mulder H, **Bjartell A**, Blom AM. Cartilage Oligomeric Matrix Protein promotes prostate cancer progression by enhancing invasion and disrupting the intracellular calcium homeostasis. *Oncotarget.* 2017 Sep 21;8(58):98298-98311.

234. Bruinsma SM, Zhang L, Roobol MJ, Bangma CH, Steyerberg EW, Nieboer D, Van Hemelrijck M; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (**GAP3**) consortium. [The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date.](#) *BJU Int.* 2018 May;121(5):737-744.

235. Vickers A, Vertosick EA, Sjoberg DD, Hamdy F, Neal D, **Bjartell A**, Hugosson J, Donovan JL, Villers A, Zappala S, Lilja H. [Value of intact prostate specific antigen and human kallikrein 2 in the four kallikrein predictive model: an individual patient data meta-analysis.](#) *J Urol.* 2018 June;199(6):1470-1474

236. Wallerstedt A, Nyberg T, Carlsson S, Thorsteinsdottir T, Stranne J, Tyrizis SI, Stinesen Kollberg K, Hugosson J, **Bjartell A**, Wilderäng U, Wiklund P, Steineck G, Haglind E. [Quality of Life After Open Radical Prostatectomy Compared with Robot-assisted Radical Prostatectomy.](#) *Eur Urol Focus.* 2019 May;5(3):389-398

237. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Viridi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; **PRECISION Study Group Collaborators.** [MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.](#) *N Engl J Med.* 2018 May 10;378(19):1767-1777.

238. Prencipe M, Fabre A, Murphy TB, Vargyas E, O'Neill A, **Bjartell A**, Tasken KA, Grytli HH, Svindland A, Berge V, Eri LM, Gallagher W, Watson RW. [Role of serum response factor expression in prostate cancer biochemical recurrence.](#) *Prostate.* 2018 Jul;78(10):727-730

239. Reza M, Kaboteh R, Sadik M, **Bjartell A**, Wollmer P, Trägårdh E. [A prospective study to evaluate the intra-individual reproducibility of bone scans for quantitative assessment in patients with metastatic prostate cancer.](#) *BMC Med Imaging.* 2018 May 4;18(1):8.

240. Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, **Bjartell A**, Widmark A, Sternberg CN,

- Pili R, Tuveson H, Nordle Ö, Carducci M, Morris MJ. Phase 3 validation of the automated Bone Scan Index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer. *JAMA Oncol*, 2018 Jul;4(7):944-951
241. Forsmark A, Gehrman J, Angenete E, **Bjartell A**, Björholt I, Carlsson S, Hugosson J, Marlow T, Stinesen-Kollberg K, Steineck G, Stranne J, Wallerstedt A, Wiklund P, Wilderäng U, Haglind E. Health economic analysis of open and robot-assisted laparoscopic surgery for prostate cancer within the prospective multi-centre LAPPRO trial. *Eur Urol* 2018 Dec;74(6):816-824.
242. Davis NF, Jack GS, Witjes WP, **Bjartell A**, Caris C, Patel A, de la Taille A, Lawrentschuk N, Bolton DM, Tubaro A. Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE): a cost minimisation analysis. *World J Urol*. 2019 May;37(5):873-878.
243. Flores-Morales A, Bergmann TB, Lavalley C, Batth TS, LIN D, Lerdrup M, Friis S, XUE H, Fazli L, Hansen KH, **Bjartell A**, Wang Y, Olsen JV, Collins CC and Iglesias-Gato D. Proteogenomic characterization of patient derived xenografts revealed the role of REST in castration-resistant neuroendocrine prostate cancer. *Clin Cancer Res*. 2019 Jan 15;25(2):595-608.
244. Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, van der Linden W, Nieboer D, Bangma CH, Frydenberg M, Rannikko A, Lee LS, Gnanapragasam VJ, Kattan MW; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance **GAP3 consortium**. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. *Eur Urol*. 2019 Mar;75(3):523-531.
245. Wallerstedt Lantz A, Stranne J, Tyritzis SI, Bock D, Wallin D, Nilsson H, Carlsson S, Thorsteinsdottir T, Gustafsson O, Hugosson J, **Bjartell A**, Wiklund P, Steineck G, Haglind E. 90-Day readmission after radical prostatectomy-a prospective comparison between robot-assisted and open surgery. *Scand J Urol*. 2019 Feb;53(1):26-33.
246. Perez-Cornago A, Huybrechts I, Appleby PN, Schmidt JA, Crowe FL, Overvad K, Tjønneland A, Kühn T, Katzke V, Trichopoulou A, Karakatsani A, Peppas E, Grioni S, Palli D, Sacerdote C, Tumino R, Bueno-de-Mesquita HB, Larrañaga N, Sánchez MJ, Quirós JR, Ardanaz E, Chirlaque MD, Agudo A, **Bjartell A**, Wallström P, Chajes V, Tsilidis KK, Aune D, Riboli E, Travis RC, Key TJ. Intake of individual fatty acids and risk of prostate cancer in the European prospective investigation into cancer and nutrition. *Int J Cancer*. 2020 Jan 1;146(1):44-57.
247. **Bjartell A**. New Hope in Prostate Cancer Precision Medicine? miRNA Replacement and Epigenetics. *Clin Cancer Res*. 2019 May 1;25(9):2679-2681.
248. Erestam S, Bock D, Erichsen Andersson A, **Bjartell A**, Carlsson S, Stinesen Kollberg K, Sjöberg D, Steineck G, Stranne J, Thorsteinsdottir T, Tyritzis S, Wallerstedt Lantz A, Wiklund P, Angenete E, Haglind E. Associations between intraoperative factors and surgeons' self-assessed operative satisfaction. *Surg Endosc*. 2020 Jan;34(1):61-68.
249. Krzyzanowska A, Don-Doncow N, Marginean FE, Gaber A, Watson RW, Hellsten R, **Bjartell A**. Expression of tSTAT3, pSTAT3⁷²⁷ and pSTAT3⁷⁰⁵ in the epithelial cells of hormone-naïve prostate cancer. *The Prostate* 2019 May;79(7):784-797.
250. Bock D, Angenete E, **Bjartell A**, Hugosson J, Steineck G, Walming S, Wiklund P, Haglind E. Agreement between patient reported outcomes and clinical reports after radical prostatectomy - a prospective longitudinal study. *BMC Urol*. 2019 May 8;19(1):35.

251. Chi KN, Agarwal N, **Bjartell** A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. *N Engl J Med*. 2019 Jul 4;381(1):13-24.
252. Nyberg M, Hugosson J, Wiklund P, Sjöberg D, Wilderäng U, Carlsson SV, Carlsson S, Stranne J, Steineck G, Haglind E, **Bjartell** A, on behalf of the LAPPRO group. Functional and oncologic outcomes between open and robotic radical prostatectomy at 24 - months follow - up in the Swedish LAPPRO trial. *Eur Urol Oncol*. 2018 Oct;1(5):353-360.
253. Reza M, Wirth M, Tammela T, Cicalese V, Veiga FG, Mulders P, Miller K, Tubaro A, Debruyne F, Patel A, Caris C, Witjes W, Thorsson O, Wollmer P, Edenbrandt L, Ohlsson M, Trägårdh E, **Bjartell** A. Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11. *Eur Urol Oncol*. 2021 Feb;4(1):49-55.
254. van der Kwast TH, Helleman J, Nieboer D, Bruinsma SM, Roobol MJ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium, Trock B, Ehdaie B, Carroll P, Filson C, Kim J, Logothetis C, Morgan T, Klotz L, Pickles T, Hyndman E, Moore CM, Gnanapragasam V, Van Hemelrijck M, Dasgupta P, Bangma C, Roobol M, Villers A, Rannikko A, Valdagni R, Perry A, Hugosson J, Rubio-Briones J, Bjartell A, Hefermehl L, Shiong LL, Frydenberg M, Kakehi Y, Chung BH, van der Kwast T, Obbink H, van der Linden W, Hulsen T, de Jonge C, Kattan M, Xinge J, Muir K, Lophatananon A, Fahey M, Steyerberg E, Nieboer D, Zhang L, Guo W, Benfante N, Cowan J, Patil D, Tolosa E, Kim TK, Mamedov A, LaPointe V, Crump T, Kimberly-Duffell J, Santaolalla A, Nieboer D, Olivier JT, Rancati T, Ahlgren H, Mascarós J, Löfgren A, Lehmann K, Lin CH, Hiramata H, Lee KS, Jenster G, Auvinen A, **Bjartell** A, Haider M, van Bochove K, Carter B, Gledhill S, Buzza M, Bangma C, Roobol M, Bruinsma S, Helleman J. Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. *Eur Urol Oncol*. 2019 May;2(3):333-336.
255. Malde S, Patel A, Martínez-Piñero L, de la Taille A, **Bjartell** A, Tubaro A, Witjes W, Caris C. Incidence of Nocturia in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement and Outcomes After Medical Treatment: Results from the Evolution European Association of Urology Research Foundation Prospective Multinational Registry. *Eur Urol Focus*. 2021 Jan;7(1):178-185.
256. Hellsten R, Lilljebjörn L, Johansson M, Leandersson K, **Bjartell** A. The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors. *The Prostate*, 2019 Oct;79(14):1611-1621.
257. Braadland PR, Ramberg H, Grytli HH, Urbanucci A, Nielsen HK, Guldvik IJ, Engedal A, Ketola K, Wang W, Svindland A, Mills IG, **Bjartell** A, Taskén KA. The β_2 -Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells. *Mol Cancer Res*. 2019 Nov;17(11):2154-2168.
258. Tyrirtis SI, Wilderäng U, Lantz AW, Steineck G, Hugosson J, **Bjartell** A, Stranne J, Haglind E, Wiklund NP. Hospital readmissions after limited vs. extended lymph node dissection during open and robot-assisted radical prostatectomy. *Urol Oncol*. 2020 Jan;38(1):5.e1-5.e8.
259. Drost FH, Nieboer D, Morgan TM, Carroll PR, Roobol MJ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (**GAP**) Consortium. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.

260. Kalapara AA, Verbeek JFM, Nieboer D, Fahey M, Gnanapragasam V, Van Hemelrijck M, Lee LS, Bangma CH, Steyerberg EW, Harkin T, Helleman J, Roobol MJ, Frydenberg M; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (**GAP3**)

Consortium. Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. *Eur Urol Oncol.* 2020 Feb;3(1):80-91.

261. Agarwal N, McQuarrie K, **Bjartell** A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Özgüroğlu M, Juárez Soto Á, Merseburger AS, Uemura H, Ye D, Given R, Cella D, Basch E, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi KN; TITAN investigators. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. *Lancet Oncol.* 2019 Nov;20(11):1518-1530.

262. Anand A, Tragardh E, Edenbrandt L, Beckman L, Svensson JH, Thellenberg C, Widmark A, Kindblom J, Ullén A, **Bjartell** A. Assessing Radiographic Response to Ra-223 with Automated Bone Scan Index (aBSI) in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients. *J Nucl Med.* 2020 May;61(5):671-675.

263. Papadimitriou N, Muller D, van den Brandt PA, Geybels M, Patel CJ, Gunter MJ, Lopez DS, Key TJ, Perez-Cornago A, Ferrari P, Vineis P, Weiderpass E, Boeing H, Agudo A, Sánchez MJ, Overvad K, Kühn T, Fortner RT, Palli D, Drake I, **Bjartell** A, Santiuste C, Bueno-de-Mesquita BH, Krogh V, Tjønneland A, Lauritzen DF, Gurrea AB, Quirós JR, Stattin P, Trichopoulou A, Martimianaki G, Karakatsani A, Thysell E, Johansson I, Ricceri F, Tumino R, Larrañaga N, Khaw KT, Riboli E, Tzoulaki I, Tsilidis KK. A nutrient-wide association study for risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition and the Netherlands Cohort Study. *Eur J Nutr.* 2020 Oct;59(7):2929-2937.

265. Alghazali M, Löfgren A, Jørgensen L, Svensson M, Fagerlund K, **Bjartell** A. A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide. *Scand J Urol.* 2019 Oct;53(5):312-318.

266. Smith EJ, Plass K, Darraugh J, Shepherd R, Briganti A, Cornford P, Knoll T, Lumen N, N'Dow J, Ribal MJ, Sylvester R, van Poppel H, **Bjartell** A; EAU Guidelines Office Panel Chairs. European Association of Urology Guidelines Office: How We Ensure Transparent Conflict of Interest Disclosure and Management. *Eur Urol.* 2020 Apr;77(4):397-399.

267. Gillessen S, Attard G, Beer TM, Beltran H, **Bjartell** A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efsthathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. *Eur Urol.* 2020 Apr;77(4):508-547.

269. Alghazali M, Löfgren A, Cheng N, Fagerlund K, **Bjartell** A. Update on a real-world study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-

resistant prostate cancer treated with enzalutamide. *Scand J Urol*. 2020 Jun;54(3):263-264.

270. Bock D, Angenete E, Asplund D, **Bjartell** A, Carlsson S, Hugosson J, Stinesen Kollberg K, Lantz A, Nilsson H, Prytz M, Steineck G, Thorsteinsdottir T, Wiklund P, Haglind E. Do negative intrusive thoughts at diagnosis predict impaired quality of life, depressed mood and waking up with anxiety 3, 12 and 24 months after radical prostatectomy? - a longitudinal study. *Scand J Urol*. 2020 Jun;54(3):220-226.

271. Bhatt NR, Davis NF, Witjes WP, **Bjartell** A, Caris C, Patel A, de la Taille A, Tubaro A. Quality of life with pharmacological treatment in patients with benign prostatic enlargement: results from the Evolution European Prospective Multicenter Multi-National Registry Study. *World J Urol*. 2021 Feb;39(2):517-526.

272. Grimm MO, van der Heijden AG, Colombel M, Muilwijk T, Martínez-Piñeiro L, Babjuk MM, Türkeri LN, Palou J, Patel A, **Bjartell** AS, Caris C, Schipper RG, Witjes WPJ; EAU Research Foundation NIMBUS Study Group. Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS". *Eur Urol*. 2020 Nov;78(5):690-698.

273. Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuizen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; **HERO Study Investigators**. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. *N Engl J Med*. 2020 Jun 4;382(23):2187-2196.

274. Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M; **PROSPER Investigators**. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med*. 2020 Jun 4;382(23):2197-2206.

275. Chowdhury S, **Bjartell** A, Lumen N, Maroto P, Paiss T, Gomez-Veiga F, Birtle A, Kramer G, Kalinka E, Spaëth D, Feyerabend S, Matveev V, Lefresne F, Lukac M, Wapenaar R, Costa L. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. *Target Oncol*. 2020 Jun;15(3):301-315.

276. Tomer A, Nieboer D, Roobol MJ, **Bjartell** A, Steyerberg EW, Rizopoulos D; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. *BJU Int*. 2021 Jan;127(1):96-107.

277. Fanti S, Goffin K, Hadaschik BA, Herrmann K, Maurer T, MacLennan S, Oprea-Lager DE, Oyen WJ, Rouvière O, Mottet N, **Bjartell** A. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. *Eur J Nucl Med Mol Imaging*. 2021 Feb;48(2):469-476.

278. Canesin G, Maggio V, Palominos M, Stiehm A, Contreras HR, Castellón EA, Morote J, Paciucci R, Maitland NJ, **Bjartell** A, Hellsten R. STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population. *Sci Rep*. 2020 Aug 18;10(1):13958.

279. Canesin G, Di Ruscio A, Li M, Ummarino S, Hedblom A, Choudhury R, Krzyzanowska A, Csizmadia E, Palominos M, Stiehm A, Ebralidze A, Chen SY, Bassal MA, Zhao P, Tolosano E, Hurley L, **Bjartell** A, Tenen DG, Wegiel B. Scavenging of Labile Heme by Hemopexin Is a Key Checkpoint in Cancer Growth and Metastases. *Cell Rep*. 2020 Sep 22;32(12):108181.

280. Cornford P, Smith EJ, MacLennan S, Pereira-Azevedo N, Roobol MJ, Lumen N, Fullwood L,

Duncan E, Dunsmore J, Plass K, Ribal MJ, Knoll T, **Bjartell** A, Van Poppel H, N'Dow J, Briganti A; Pan-European National Urological Society IMAGINE Collaborative.

IMAGINE-IMPact Assessment of Guidelines Implementation and Education: The Next Frontier for Harmonising Urological Practice Across Europe by Improving Adherence to Guidelines. *Eur Urol* 2021 Feb;79(2):173-176.

281. Modig KK, Godtman RA, **Bjartell** A, Carlsson S, Haglind E, Hugosson J, Månsson M, Steineck G, Thorsteinsdottir T, Tyritzis S, Lantz AW, Wiklund P, Stranne J. Vesicourethral Anastomotic Stenosis After Open or Robot-assisted Laparoscopic Retropubic Prostatectomy-Results from the Laparoscopic Prostatectomy Robot Open Trial. *Eur Urol Focus*. 2021 Mar;7(2):317-324.

282. Fridhammar A, Axelsson U, Persson U, **Bjartell** A, Borrebaeck CAK. The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development. *Pharmacoecon Open* 2021 Mar;5(1):77-88.

283. Nyberg M, Sjöberg DD, Carlsson SV, Wilderäng U, Carlsson S, Stranne J, Wiklund P, Steineck G, Haglind E, Hugosson J, **Bjartell** A. Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial. *BJU Int*. 2021 Mar;127(3):361-368.

284. Micke P, Strell C, Mattsson J, Martín-Bernabé A, Brunnström H, Huvila J, Sund M, Wärnberg F, Ponten F, Glimelius B, Hrynchuk I, Mauchanski S, Khelashvili S, Garcia-Vicién G, Molleví DG, Edqvist PH, O Reilly A, Corvigno S, Dahlstrand H, Botling J, Segersten U, Krzyzanowska A, **Bjartell** A, Elebro J, Heby M, Lundgren S, Hedner C, Borg D, Brändstedt J, Sartor H, Malmström PU, Johansson M, Nodin B, Backman M, Lindskog C, Jirström K, Mezheyeuski A. The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types. *EBioMedicine*. 2021 Mar;65:103269. doi: 10.1016/j.ebiom.2021.103269. Epub 2021 Mar 9.

285. Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, Nieboer D, Bangma C, Frydenberg M, Rannikko A, Lee LS, Gnanapragasam V, Kattan MW; **Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium**. A first step towards a global nomogram to predict disease progression for men on active surveillance. *Transl Androl Urol*. 2021 Mar;10(3):1102-1109. doi: 10.21037/tau-20-1082.

286. Welén K, Överby AK, Ahlm C, Freyhult E, Robinsson D, Henningsson AJ, Stranne J, Bremell D, Angelin M, Lindquist E, Buckland R, Carlsson CT, Pauksens K, Bill-Axelsson A, Akre O, Ryden C, Wagenius M, **Bjartell** A, Nilsson AC, Styrke J, Repo J, Balkhed ÅÖ, Niward K, Gisslén M, Josefsson A. COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial. *Trials*. 2021 Mar 16;22(1):209. doi: 10.1186/s13063-021-05137-4.

287. Trägårdh E, Simoulis A, **Bjartell** A, Jogi J. Tumor detection of ¹⁸F-PSMA-1007 in the prostate gland in patients with prostate cancer using prostatectomy specimens as reference method. *J Nucl Med*. 2021 Mar 31:jnumed.121.261993. doi: 10.2967/jnumed.121.261993.

288. Nyberg M, Akre O, Bock D, Carlsson SV, Carlsson S, Hugosson J, Lantz A, Steineck G, Stranne J, Tyritzis S, Wiklund P, Haglind E, **Bjartell** A. Risk of recurrent disease 6 years after open or robotic-assisted radical prostatectomy in the prospective controlled trial LAPPRO. *Eur Urol Open Sci*, 2020 54-61.

289. Tubaro A, Speakman M, de la Taille A, Martínez-Piñeiro L, Berges R, Patel A, **Bjartell** A, Caris C, Witjes W. A European Registry Evaluating Symptomatic Effectiveness of Pharmacologically Treated Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Enlargement: Lessons

290. Emruli VK, Liljedahl L, Axelsson U, Richter C, Theorin L, **Bjartell** A, Lilja H, Donovan J, Neal D, Hamdy FC, Borrebaeck CAK. Identification of a serum biomarker signature associated with metastatic prostate cancer. *Proteomics Clin Appl*. 2021 Feb 13:e2000025. doi: 10.1002/prca.202000025.
291. **Bjartell** A, Lumen N, Maroto P, Paiss T, Gomez-Veiga F, Birtle A, Kramer G, Kalinka E, Spaeth D, Feyerabend S, Matveev V, Lefresne F, Lukac M, Wapenaar R, Costa L, Chowdhury S. Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry. *Target Oncol*. 2021 May;16(3):357-367.
292. Crump RT, Remmers S, Van Hemelrijck M, Helleman J, Nieboer D, Roobol MJ, Venderbos LDF; **Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium.** Using the Movember Foundation's GAP3 cohort to measure the effect of active surveillance on patient-reported urinary and sexual function-a retrospective study in low-risk prostate cancer patients. *Transl Androl Urol*. 2021 Jun;10(6):2719-2727.
293. Bhatt NR, Davis NF, Witjes WP, **Bjartell** A, Caris C, Patel A, de la Taille A, Speakman M, Martínez-Piñero L, Tubaro A. Contemporary use of phytotherapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: results from the EVOLUTION European registry. *World J Urol*. 2020 Oct 16. doi: 10.1007/s00345-020-03480-w. Online ahead of print.
294. Bruinsma SM, Nieboer D, Roobol MJ, Bangma CH, Verbeek JFM, Gnanapragasam V, Van Hemelrijck M, Frydenberg M, Lee LS, Valdagni R, Logothetis C, Steyerberg EW; the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative. *J Urol*. 2021 Jul;206(1):62-68.
295. Chi K, Chowdhury S, **Bjartell** A, Ha Chung B, Pereira de Santana Gomes A, Given R, Juárez Soto A, Merseburger A, Özgüroğlu M, Uemura H, Ye D, Brookman-May S, Mundle S, McCarthy S, Larsen JS, Sun W, Bevans KN, Zhang K, Bandyopadhyay N, Agarwal N. Apalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. *J Clin Oncol*. 2021 Jul 10;39(20):2294-2303.
296. Puterman C, Bjöersdorff M, Amidi J, Anand A, Soller W, Jiborn T, Kjölhede H, Trägårdh^m E, **Bjartell**. A retrospective study assessing the accuracy of [18F]-fluorocholine PET/CT for primary staging of lymph node metastases in intermediate and high-risk prostate cancer patients undergoing robotic-assisted laparoscopic prostatectomy with extended lymph node dissection. *Scand J Urol*. 2021 Aug;55(4):293-297.
297. Axén E, Godtman RA, **Bjartell** A, Carlsson S, Haglind E, Hugosson J, Lantz A, Månsson M, Steineck G, Wiklund P, Stranne J. Degree of Preservation of Neurovascular Bundles in Radical Prostatectomy and Recurrence of Prostate Cancer. *Eur Urol Open Sci*. 2021 Jun 19;30:25-33.
298. Marginean F, Arvidsson I, Simoulis A, Overgaard NC, Åström K, Heyden A, **Bjartell** A, Krzyzanowska A. An artificial intelligence-based support tool for automation and standardization of Gleason grading in prostate biopsies. *Eur Urol Focus* 2020 Dec 7:S2405-4569(20)30296-0. doi: 10.1016/j.euf.2020.11.001. Online ahead of print.
299. Hagman A, Lantz A, Carlsson S, Höijer J, Stranne J, Tyritzis SI, Haglind E, **Bjartell** A, Hugosson J, Akre O, Steineck G, Wiklund P. Urinary continence recovery and oncological outcomes

after surgery for prostate cancer analysed by risk category: results from the LAParoscopic prostatectomy robot and open trial. *World J Urol.* 2021 Mar 20. doi: 10.1007/s00345-021-03662-0. Online ahead of print.

300. Beyer K, MacLennan SJ, Moris L, Lardas M, Mastris K, Hooker G, Greene R, Briers E, Omar MI, Healey J, Tripathy S, Gandaglia G, Venderbos LDF, Smith EJ, Bjorkqvist J, Asiimwe A, Huber J, Roobol MJ, Zong J, **Bjartell A**, N'Dow J, Briganti A, MacLennan S, Van Hemelrijck M; PIONEER Consortium; EAU; LU; UNISR; Erasmus; UKE; TAU; KCL; EORTC; TTOP; ICHOM; ECPC; ASSOC EISBM; ICL; Hyve; EAPM; PM; WI; UoA; TUD; Fraunhofer; UGOT; Radboud; IHE; Bayer AG; SANOFI; ASTELLAS; SAS; Janssen; IQVIA; eGF-eCancer; AstraZeneca; HelmHoltz. *Eur Urol Focus.* 2021 Sep 30:S2405-4569(21)00237-6.

301. Agarwal N, McQuarrie K, **Bjartell A**, Chowdhury S, Pereira de Santana Gomes AJ, Ha Chung B, Özgüroğlu M, Juárez Soto A, Merseburger AS, Uemura H, Ye D, Given R, Basch E, Miladinovic B, Lopez-Gitlitz A, Chi KN. Apalutamide Plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the TITAN Study. *J Urol.* 2021 Oct;206(4):914-923.

302. Witt K, Evans-Axelsson S, Lundqvist A, Johansson M, **Bjartell A**, Hellsten R. Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer. *Cancer Immunol Immunother.* 2021 Nov;70(11):3155-3166.

303. Voss G, Edsjö A, **Bjartell A**, Ceder Y. Quantification of microRNA editing using two-tailed RT-qPCR for improved biomarker discovery. *RNA.* 2021 Aug 25:rna.078867.121. doi: 10.1261/rna.078867.121..

304. Vertosick EA, Zappala S, Punnen S, Hugosson J, Boorjian SA, Haese A, Carroll P, Cooperberg M, **Bjartell A**, Lilja H, Vickers AJ. Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. *Urology.* 2021 Aug 24:S0090-4295(21)00793-7.

305. Lantz A, Bock D, Akre O, Angenete E, **Bjartell A**, Carlsson S, Koss Modig K, Nyberg M, Stinesen Kollberg K, Steineck G, Stranne J, Wiklund P, Haglund E. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. *Eur Urol* 2021 Sep 15:S0302-2838(21)01928-X. doi: 10.1016/j.eururo.2021.07.025. Online ahead of print.

306. Beckmann K, Santaolalla A, Helleman J, Carroll P, Ha Chung B, Shiong Lee L, Perry A, Rubio-Briones J, Sugimoto M, Trock B, Valdagni R, Dasgupta P, Van Hemelrijck M, Elhage O; **Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium.** Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database. *Eur Urol Open Sci.* 2021 Nov 1;34:47-54.

307. Klotz L, Grudén S, Axén N, Gauffin C, Wassberg C, **Bjartell A**, Giddens J, Incze P, Jansz K, Jievaltas M, Rendon R, Richard PO, Ulys A, Tammela TL. Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients. *Eur Urol Focus.* 2021 Feb 11:S2405-4569(21)00046-8. doi: 10.1016/j.euf.2021.02.003. Online ahead of print

308. Olivier J, Li W, Nieboer D, Helleman J, Roobol M, Gnanapragasam V, Frydenberg M, Sugimoto M, Carroll P, Morgan TM, Valdagni R, Rubio-Briones J, Robert G, Stricker P, Hayen A, Schoots I, Haider M, Moore CM, Denton B, Villers A; **Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 Consortium.** Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of

Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. *Eur Urol Open Sci.* 2022 Jan 3;35:59-67. doi: 10.1016/j.euros.2021.11.006. PMID: 35024633; PMCID: PMC8738894.

309. Nilsson H, Stranne J, Hugosson J, Wessman C, Steineck G, Bjartell A, Carlsson S, Thorsteinsdottir T, Tyrirtis SI, Lantz A, Wiklund P, Haglind E. Risk of hernia formation after radical prostatectomy: a comparison between open and robot-assisted laparoscopic radical prostatectomy within the prospectively controlled LAPPRO trial. *Hernia.* 2022 Feb;26(1):157-164. doi: 10.1007/s10029-020-02178-7. Epub 2020 Apr 11. Erratum in: *Hernia.* 2022 Apr;26(2):683.

310. Johnsson K, Brynolfsson J, Sahlstedt H, Nickols NG, Rettig M, Probst S, Morris MJ, **Bjartell A**, Eiber M, Anand A. Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [¹⁸F]DCFPyL (PSMA) imaging for standardized reporting. *Eur J Nucl Med Mol Imaging.* 2021 Aug 31.

311. Welén K, Rosendal E, Gisslén M, Lenman A, Freyhult E, Fonseca-Rodríguez O, Bremell D, Stranne J, Balkhed ÅÖ, Niward K, Repo J, Robinsson D, Henningsson AJ, Styrke J, Angelin M, Lindquist E, Allard A, Becker M, Rudolfsson S, Buckland R, Carlsson CT, **Bjartell A**, Nilsson AC, Ahlm C, Connolly AF, Överby AK, Josefsson A. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. *Eur Urol.* 2022 Mar;81(3):285-293. doi: 10.1016/j.eururo.2021.12.013. Epub 2021 Dec 15.

312. Olivier J, Li W, Nieboer D, Helleman J, Roobol M, Gnanapragasam V, Frydenberg M, Sugimoto M, Carroll P, Morgan TM, Valdagni R, Rubio-Briones J, Robert G, Stricker P, Hayen A, Schoots I, Haider M, Moore CM, Denton B, Villers A; **Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 Consortium.** Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. *Eur Urol Open Sci.* 2022 Jan 3;35:59-67.

313. Marginean FE, Hellsten R, Krzyzanowska A, **Bjartell A.** Nuclear expression of pSTAT3^{Tyr705} and pSTAT3^{Ser727} in the stromal compartment of localized hormone-naïve prostate cancer. *Pathol Res Pract.* 2022 Apr;232:153811.

314. Beckmann KR, Bangma CH, Helleman J, **Bjartell A**, Carroll PR, Morgan T, Nieboer D, Santaolalla A, Trock BJ, Valdagni R, Roobol MJ. Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. *Global Action Plan Active Surveillance Prostate Cancer [G.A.P.3] Consortium.* Prostate. 2022 May;82(7):876-879.

315. Carlsson S, Bottai M, Lantz A, **Bjartell A**, Hugosson J, Steineck G, Stranne J, Wiklund P, Haglind E, Akre O. Lymph swelling after radical prostatectomy and pelvic lymph node dissection. *BJU Int.* 2022 Feb 7.

316. Anand A, Heller G, Fox J, Danila DC, **Bjartell A**, Edenbrandt L, Larson SM, Scher HI, Morris MJ. Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men with Metastatic Castration-Resistant Prostate Cancer. *Clin Genitourin Cancer.* 2022 Feb 9:S1558-7673(22)00037-4.

317. Bock D, Nyberg M, Lantz A, Carlsson SV, Sjöberg DD, Carlsson S, Stranne J, Steineck G, Wiklund P, Haglind E, **Bjartell A.** Learning curve for robot-assisted laparoscopic radical prostatectomy in a large prospective multicentre study. *Scand J Urol.* 2022 May 12:1-9.

318. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, **Bjartell A**, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khaulil RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeonunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. *Eur Urol.* 2022 Jul;82(1):6-11. doi: 10.1016/j.eururo.2022.02.010. Epub 2022 Feb 17. Erratum in: *Eur Urol.* 2022 Jul;82(1):e18-e19.

319. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, **Bjartell A**, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khaulil RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. *Eur Urol.* 2022 Jul;82(1):115-141.

320. Remmers S, Helleman J, Nieboer D, Trock B, Hyndman ME, Moore CM, Gnanapragasam V, Shiong Lee L, Elhage O, Klotz L, Carroll P, Pickles T, Bjartell A, Robert G, Frydenberg M, Sugimoto M, Ehdaie B, Morgan TM, Rubio-Briones J, Semjonow A, Bangma CH, Roobol MJ; **Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium.** Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative. *Eur Urol Open Sci.* 2022 Jun 14;41:126-133.

321. Beckmann K, Santaolalla A, Sugimoto M, Carroll P, Rubio J, Villers A, **Bjartell A**, Morgan T, Dasgupta P, Van Hemelrijck M, Elhage O; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Risk of progression following a negative biopsy in prostate cancer active surveillance. *Prostate Cancer Prostatic Dis.* 2022 Aug 25.

322. Marenghi C, Qiu Z, Helleman J, Nieboer D, Rubio-Briones J, Carroll PR, Lee LS, Valdagni R, Boutros PC, Nicolai N; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (**GAP3**) Consortium. Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort. *Cancers (Basel).* 2022 Jul 22;14(15):3558.

323. Trägårdh E, Enqvist O, Ulén J, Hvittfeldt E, Garpered S, Lindgren Belal S, **Bjartell A**, Edenbrandt L. Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians. *Eur J Nucl Med Mol Imaging.* 2022 Apr 27.

324. Fanti S, Kunikowska J, Walz J, Witjes W, **Bjartell A**. EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([¹⁷⁷Lu]Lu-PSMA). *Eur J Nucl Med Mol Imaging.* 2022

325. Probst S, **Bjartell A**, Anand A, Skamene T, Ferrario C. Interval Changes in PSMA PET/CT During Radium-223 Therapy for Metastatic Bone Disease from Castration-Resistant Prostate Cancer. *Nucl Med Mol Imaging.* 2022 Aug;56(4):188-195.

326. Ingvar J, Hvittfeldt E, Trägårdh E, Simoulis A, **Bjartell A**. Assessing the accuracy of [¹⁸F]PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients. *EJNMMI Res.* 2022 Aug 9;12(1):48

327. Ljungquist O, Persmark A, Grabe M, Jakobsen AK, Gerdtsen A, Torisson G, **Bjartell A**, Riesbeck K. Increasing rates of urinary and bloodstream infections following transrectal prostate biopsy in South Sweden. *BJU Int.* 2022 Feb 16.

328. Fanti S, Briganti A, Emmett L, Fizazi K, Gillessen S, Goffin K, Hadaschik BA, Herrmann K, Kunikowska J, Maurer T, MacLennan S, Mottet N, Murphy DG, Oprea-Lager DE, O'Sullivan JM, Oyen WJG, Rouvière O, Sartor O, Stenzl A, Van Poppel H, Walz J, Witjes W, **Bjartell A**. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy. *Eur Urol Oncol.* 2022 Oct;5(5):530-536.

329. Hellsten R, Stiehm A, Palominos M, Persson M, **Bjartell A**. The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells. *Transl Oncol.* 2022 Oct;24:101495.

330. Alterbeck M, Järbur E, Thimansson E, Wallström J, Bengtsson J, Björk-Eriksson T, **Bjartell A**, Bratt O, Jiborn T, Arnsrud Godtman R. Designing and Implementing a Population-based Organised Prostate Cancer Testing Programme. *Eur Urol Focus.* 2022 Jul 7:S2405-4569(22)00135-3.

331. Bjöersdorff M, Puterman C, Oddstig J, Amidi J, Zackrisson S, Kjölhede H, **Bjartell A**, Wollmer P, Trägårdh E. Detection of lymph node metastases in patients with prostate cancer: Comparing conventional and digital [¹⁸F]-fluorocholine PET-CT using histopathology as a reference. *Clin Physiol Funct Imaging.* 2022 Nov;42(6):381-388.

332. Mucci LA, Vinson J, Gold T, Gerke T, Filipenko J, Green RM, Anderson SG, Badal S, **Bjartell A**, Chi KN, Davis ID, Enting D, Fay AP, Lazarus J, Mateo J, McDermott R, Odedina FT, Olmos D, Omlin A, Popoola AA, Ragin C, Roberts R, Russnes KM, Waihenya C, Stopsack KH, Hyslop T, Villanti P, Kantoff PW, George DJ; IRONMAN Global Team. IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer. *JCO Glob Oncol.* 2022 Nov;8:e2200154.

333. **Bjartell A**, Costa L, Kramer G, Zurawski B, Galli L, Werbrouck P, Ecke T, Parikh O, Bennamoun M, Garcia Freire C, Peer A, Ljungberg B, Cicin I, Smith E, Lukac M, Wapenaar R, Chowdhury S. Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry. *Eur Urol Open Sci.* 2022 Sep 17;45:12-22.

334. Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, **Bjartell A**, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley

DA, Feng FY. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. *Cancer Res.* 2022 Nov 2;82(21):3888-3902:

335. Schmidt JA, Huybrechts I, Overvad K, Eriksen AK, Tjønneland A, Kaaks R, Katzke V, Schulze MB, Pala V, Sacerdote C, Tumino R, Bueno-de-Mesquita B, Sánchez MJ, Huerta JM, Barricarte A, Amiano P, Agudo A, **Bjartell A**, Stocks T, Thysell E, Wennberg M, Weiderpass E, Travis RC, Key TJ, Perez-Cornago A. Protein and amino acid intakes in relation to prostate cancer risk and mortality-A prospective study in the European Prospective Investigation into Cancer and Nutrition. *Cancer Med.* 2022 Sep 23.

336. Bengtsson J, Thimansson E, Baubeta E, Zackrisson S, Sundgren PC, **Bjartell A**, Flondell-Sité D. Correlation between ADC, ADC ratio, and Gleason Grade group in prostate cancer patients undergoing radical prostatectomy: Retrospective multicenter study with different MRI scanners. *Front Oncol.* 2023 Feb 20;13:1079040.

337. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, **Bjartell A**, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efsthathiou E, Efsthathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khamis MM, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. See abstract for full author list. *Eur Urol.* 2023 Mar;83(3):267-293.

338. Thimansson E, Bengtsson J, Baubeta E, Engman J, Flondell-Sité D, **Bjartell A**, Zackrisson S. Deep learning algorithm performs similarly to radiologists in the assessment of prostate volume on MRI. *Eur Radiol.* 2023 Apr;33(4):2519-2528.

339. Lindgren Belal S, Larsson M, Holm J, Buch-Olsen KM, Sörensen J, **Bjartell A**, Edenbrandt L, Trägårdh E. Automated quantification of PET/CT skeletal tumor burden in prostate cancer using artificial intelligence: The PET index. *Eur J Nucl Med Mol Imaging.* 2023 Apr;50(5):1510-1520.

340. Asif A, Nathan A, Ng A, Khetrapal P, Chan VW, Giganti F, Allen C, Freeman A, Punwani S, Lorgelly P, Clarke CS, Brew-Graves C, Muirhead N, Emberton M, Agarwal R, Takwoingi Y, Deeks JJ, Moore CM, Kasivisvanathan V; **PRIME Trial Group.** Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate cancer in biopsy-naive men (PRIME): a prospective, international, multicentre, non-inferiority within-patient, diagnostic yield trial protocol. *BMJ Open.* 2023 Apr 5;13(4):e070280.

341. Chowdhury S, **Bjartell A**, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS, Özgüroğlu M, Juárez Soto Á, Uemura H, Ye D, Brookman-May SD, Londhe A, Bhaumik A, Mundle SD, Larsen JS, McCarthy SA, Chi KN. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. *Ann Oncol.* 2023 May;34(5):477-485.

342. Gillesen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, **Bjartell A**, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efsthathiou E, Efsthathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jerezcek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khaulil RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, ... See abstract for full author list Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. *Eur J Cancer.* 2023 May;185:178-215. 37003085
343. Carlsson S, Bock D, Lantz A, Angenete E, Koss Modig K, Hugosson J, **Bjartell A**, Steineck G, Wiklund P, Haglund E. Salvage radiotherapy after radical prostatectomy: functional outcomes in the LAPPRO trial after 8-year follow-up. *Scand J Urol.* 2023 May 11;58:11-19.
344. Beckmann K, Santaolalla A, Sugimoto M, Carroll P, Rubio J, Villers A, **Bjartell A**, Morgan T, Dasgupta P, Van Hemelrijck M, Elhage O; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Risk of progression following a negative biopsy in prostate cancer active surveillance. *Prostate Cancer Prostatic Dis.* 2023 Jun;26(2):403-409.
345. Almanza-Aguilera E, Guiñón-Fort D, Perez-Cornago A, Martínez-Huélamo M, Andrés-Lacueva C, Tjønneland A, Eriksen AK, Katzke V, Bajracharya R, Schulze MB, Masala G, Oliverio A, Tumino R, Manfredi L, Lasheras C, Crous-Bou M, Sánchez MJ, Amiano P, Colorado-Yohar SM, Guevara M, Sonestedt E, **Bjartell A**, Thysell E, Weiderpass E, Aune D, Aglago EK, Travis RC, Zamora-Ros R. Intake of the Total, Classes, and Subclasses of (Poly)Phenols and Risk of Prostate Cancer: A Prospective Analysis of the EPIC Study. *Cancers (Basel).* 2023 Aug 11;15(16):4067.
346. van Straten CGJI, Caris C, Grimm MO, Colombel M, Muilwijk T, Martínez-Piñeiro L, Babjuk MM, Türkeri LN, Palou J, Patel A, **Bjartell AS**, Witjes WPJ, van der Heijden AG, Kiemeneij LALM. Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial. *Eur Urol Open Sci.* 2023 Sep 12;56:15-24.
347. Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg J, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND; **EMBARK Study**. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. *N Engl J Med.* 2023 Oct 19;389(16):1453-1465.
348. Krzyzanowska A, Barron S, Higgins DF, Loughman T, O'Neill A, Sheehan KM, Wang CA, Fender B, McGuire L, Fay J, O'Grady A, O'Leary D, Watson RW, **Bjartell A**, Gallagher WM. Development, Validation, and Clinical Utility of a Six-gene Signature to Predict Aggressive Prostate Cancer. *Eur Urol Focus.* 2023 Nov;9(6):983-991
349. Merseburger AS, Agarwal N, Bhaumik A, Lefresne F, Karsh LI, Pereira de Santana Gomes AJ, Soto AJ, Given RW, Brookman-May SD, Mundle SD, McCarthy SA, Uemura H, Chowdhury S, Chi KN, **Bjartell A**. Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with

metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study. *Eur J Cancer*. 2023 Nov;193:113290.

350. Gomez Rivas J, Nicoletti R, Ibáñez L, Steinbeisser C, de Meulder B, Golozar A, Axelsson SE, Snijder R, **Bjartell A**, Cornford P, Van Hemelrijck M, Beyer K, Willemse PP, Murtola T, Roobol MJ, Moreno-Sierra J, Campi R, Gacci M, Mottet N, Merseburger A, Ndow J. Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI's "big data for better outcomes" program. *Int J Surg Protoc*. 2023 Oct 17;27(3):122-129

351. Gómez Rivas J, Leenen RCA, Venderbos LDF, Helleman J, de la Parra I, Vasilyeva V, Moreno-Sierra J, Basu P, Chandran A, van den Bergh RCN, Collen S, Van Poppel H, Roobol MJ, Beyer K; **The PRAISE-U Consortium**. Navigating through the Controversies and Emerging Paradigms in Early Detection of Prostate Cancer: Bridging the Gap from Classic RCTs to Modern Population-Based Pilot Programs. *J Pers Med*. 2023 Dec 1;13(12):1677.

352. Magnusson C, Augustsson P, Anand EU, Lenshof A, Josefsson A, Welén K, **Bjartell A**, Ceder Y, Lilja H, Laurell T. Acoustic enrichment of heterogenous circulating tumor cells and clusters from patients with metastatic prostate cancer. *medRxiv* [Preprint]. 2023 Dec 4:2023.12.04.23299128. doi: 10.1101/2023.12.04.23299128. Update in: *Anal Chem*. 2024 May 7;96(18):6914-6921.

353. Alterbeck M, Thimansson E, Bengtsson J, Baubeta E, Zackrisson S, Bolejko A, Sandeman K, Carlsson S, Jiborn T, **Bjartell A**. A pilot study of an organised population-based testing programme for prostate cancer. *BJU Int*. 2024 Jan;133(1):87-95.

354. Oprea-Lager DE, MacLennan S, **Bjartell A**, Briganti A, Burger IA, de Jong I, De Santis M, Eberlein U, Emmett L, Fizazi K, Gillessen S, Herrmann K, Heskamp S, Iagaru A, Jereczek-Fossa BA, Kunikowska J, Lam M, Nanni C, O'Sullivan JM, Panebianco V, Sala E, Sathekge M, Sosnowski R, Tilki D, Tombal B, Treglia G, Tunariu N, Walz J, Yakar D, Dierckx R, Sartor O, Fanti S. European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer. *Eur Urol*. 2024 Jan;85(1):49-60.

355. Russell B, Beyer K, Lawlor A, Roobol MJ, Venderbos LDF, Remmers S, Briers E, MacLennan SJ, MacLennan S, Omar MI, Van Hemelrijck M; **PIONEER Consortium**. Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be? *Eur Urol Open Sci*. 2023 Dec 19;59:27-29.

356. Thimansson E, Baubeta E, Engman J, **Bjartell A**, Zackrisson S. Deep learning performance on MRI prostate gland segmentation: evaluation of two commercially available algorithms compared with an expert radiologist. *J Med Imaging* (Bellingham). 2024 Jan;11(1):015002..

357. Lai LYH, Sakalis V, Chatzichristos C, de la Parra I, Steinbeisser C, Golozar A, de Meulder B, HijazymA, Snijder R, Feng Q, Falconer R, Cornford P, **Bjartell A**, Evans-Axelsson S, N'Dow J, Gandaglia G, Gómez Rivas J. Baseline Characteristics and Clinical Outcomes of Prostate Cancer Patients on Delayed Palliative Management: a PIONEER Analysis Based on Big Data. *Cent European J Urol*. 2024;77(3):403-410.

358. Bratt O, Godtman RA, Jiborn T, Wallström J, Akre O, Carlsson S, Nordström T, Thimansson E, Alterbeck M, Zackrisson S, Hugosson J, **Bjartell A**, Lantz A. Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men. *Eur Urol*. 2024 Mar;85(3):207-214.

359. Chowdhury S, **Bjartell A**, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS, Özgüroğlu M, Soto ÁJ, Uemura H, Ye DW, Brookman-May SD, Londhe A,

Bhaumik A, Mundle SD, Larsen JS, McCarthy SA, Chi KN. Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study. *Future Oncol.* 2024 Mar;20(10):563-578

360. Chen N, McGrath CB, Ericsson CI, Vasselkiv JB, Rencsok EM, Stopsack KH, Guard HE, Autio KA, Rathkopf DE, Enting D, Bitting RL, Mateo J, Githiaka CW, Chi KN, Cheng HH, Davis ID, Anderson SG, Badal SAM, **Bjartell A**, Russnes KM, Heath EI, Pomerantz MM, Henegan JC, Hyslop T, Esteban E, Omlin A, McDermott R, Fay AP, Popoola AA, Ragin C, Nowak J, Gerke T, Kantoff PW, George DJ, Penney KL, Mucci LA; IRONMAN Registry. Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer. *Cancer Epidemiol Biomarkers Prev.* 2024 Mar 1;33(3):419-425.

362. Beyer K, Lawlor A, Remmers S, Bezuidenhout C, Gómez Rivas J, Venderbos LDF, Smith EJ, Gandaglia G, MacLennan S, MacLennan SJ, **Bjartell A**, Briganti A, Cornford P, Evans-Axelsson S, Ribal MJ, N'Dow J, Briers E, Roobol MJ, Van Hemelrijck M; PIONEER Consortium. How Can We Improve Patient-Clinician Communication for Men Diagnosed with Prostate Cancer? *Eur Urol Open Sci.* 2024 Feb 13;62:1-7.

363. Gandaglia G, Pellegrino F, Golozar A, De Meulder B, Abbott T, Achtman A, Imran Omar M, Alshammari T, Areia C, Asiimwe A, Beyer K, **Bjartell A**, Campi R, Cornford P, Falconer T, Feng Q, Gong M, Herrera R, Hughes N, Hulsen T, Kinnaird A, Lai LYH, Maresca G, Mottet N, Oja M, Prinsen P, Reich C, Remmers S, Roobol MJ, Sakalis V, Seager S, Smith EJ, Snijder R, Steinbeisser C, Thurin NH, Hijazy A, van Bochove K, Van den Bergh RCN, Van Hemelrijck M, Willemse PP, Williams AE, Zounemat Kermani N, Evans-Axelsson S, Briganti A, N'Dow J; PIONEER Consortium. Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data *Eur Urol* 2024 May;85(5):457-465.

364. Rajwa P, Borkowetz A, Abbott T, Alberti A, **Bjartell A**, Brash JT, Campi R, Chilelli A, Conover M, Constantinovici N, Davies E, De Meulder B, Eid S, Gacci M, Golozar A, Hafeez H, Haque S, Hijazy A, Hulsen T, Josefsson A, Khalid S, Kolde R, Kotik D, Kurki S, Lambrecht M, Leung CH, Moreno J, Nicoletti R, Nieboer D, Oja M, Palanisamy S, Prinsen P, Reich C, Raffaele Resta G, Ribal MJ, Gómez Rivas J, Smith E, Snijder R, Steinbeisser C, Vandenberghe F, Cornford P, Evans-Axelsson S, N'Dow J, Willemse PM. Research Protocol for an Observational Health Data Analysis on the Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer: Big Data Analytics Using the PIONEER Platform. *Eur Urol Open Sci.* 2024 Mar 25;63:81-88.

365. Magnusson C, Augustsson P, Undvall Anand E, Lenshof A, Josefsson A, Welén K, **Bjartell A**, Ceder Y, Lilja H, Laurell T. Acoustic Enrichment of Heterogeneous Circulating Tumor Cells and Clusters from Metastatic Prostate Cancer Patients. *Anal Chem.* 2024 May 7;96(18):6914-6921.

366. Saha A, Bosma JS, Twilt JJ, van Ginneken B, **Bjartell A**, Padhani AR, Bonekamp D, Villeirs G, Salomon G, Giannarini G, Kalpathy-Cramer J, Barentsz J, Maier-Hein KH, Rusu M, Rouvière O, van den Bergh R, Panebianco V, Kasivisvanathan V, Obuchowski NA, Yakar D, Elschot M, Veltman J, Fütterer JJ, de Rooij M, Huisman H; PI-CAI consortium. Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study. *Lancet Oncol.* 2024 Jul;25(7):879-887.

367. Roth D, Safi M, Vilhelmsson Timmermand O, Sereti E, Molendowska M, Gottschalk M, **Bjartell**

- A, Ceberg C, Szczepankiewicz F, Strand J. Evaluation of superficial xenograft volume estimation by ultrasound and caliper against MRI in a longitudinal pre-clinical radiotherapeutic setting. *PLoS One*. 2024 Jul 25;19(7):e0307558.
368. Rajwa P, Robesti D, Chaloupka M, Zattoni F, Giesen A, Huebner NA, Krzywon A, Miszczyk M, Moll M, Stando R, Cisero E, Semko S, Checcucci E, Devos G, Apfelbeck M, Gatti C, Marra G, van den Bergh RCN, Goldner G, Rasul S, Ceci F, Dal Moro F, Porpiglia F, Gontero P, **Bjartell A**, Stief C, Heidenreich A, Joniau S, Briganti A, Shariat SF, Gandaglia G; EAU-Young Academic Urologists (YAU) Prostate Cancer Working Party. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study. *Eur Urol Oncol*. 2024 Aug;7(4):721-734.
369. Barclay NL, Burn E, Delmestri A, Duarte-Salles T, Golozar A, Man WY, Tan EH, Tietzova I; **OPTIMA Consortium**; Prieto-Alhambra D, Newby D. Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021. *Sci Rep*. 2024 Aug 17;14(1):19069.
370. Kristiansson A, Ceberg C, **Bjartell A**, Ceder J, Timmermand OV. Investigating Ras homolog gene family member C (RhoC) and Ki67 expression following external beam radiation therapy show increased RhoC expression in relapsing prostate cancer xenografts. *Biochem Biophys Res Commun*. 2024 Oct 8;728:150324.
371. Thimansson E, Zackrisson S, Jäderling F, Alterbeck M, Jiborn T, **Bjartell A**, Wallström J. A pilot study of AI-assisted reading of prostate MRI in Organized Prostate Cancer Testing. *Acta Oncol*. 2024 Oct 29;63:816-821
372. Merseburger AS, Agarwal N, **Bjartell A**, Uemura H, Soto AJ, Bhaumik A, Böhm J, Tran N, Krochmann N, Nematian-Samani M, Mundle SD, Brookman-May SD, Lopez-Gitlitz A, McCarthy SA, Chi K, Chowdhury S. Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy. *BJU Int*. 2024 Dec;134(6):982-991.
373. Arvidsson I, Svanemur E, Marginean F, Simoulis A, Overgaard NC, Åström K, Heyden A, Krzyzanowska A, **Bjartell A**. Artificial intelligence for detection of prostate cancer in biopsies during active surveillance. *BJU Int*. 2024 Dec;134(6):1001-1009.
374. Krzyzanowska A, Higgins DF, Barron S, Loughman T, O'Neill A, Sheehan KM, Wang CA, Fender B, McGuire L, Fay J, O'Grady A, O'Leary D, Watson RW, **Bjartell A**, Gallagher WM. Clinical validation of a biopsy-based six-gene signature prognostic for aggressive prostate cancer. *BJUJ Compass*. 2024 Dec 13;6(1):e474.
375. de Vos II, Nieboer D, Frydenberg M, Pavlovich CP, van Hemelrijck M, Lee LS, Rannikko A, Bjartell A, Semjonow A, Steyerberg EW, Roobol MJ. Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance. *JAMA Netw Open*. 2025 Jan 2;8(1):e2454366.
376. Hvittfeldt E, Hedeer F, Thimansson E, Sandeman K, Minarik D, Ingvar J, **Bjartell A**, Trägårdh E. Semi-standardized evaluation of extraprostatic extension and seminal vesicle invasion with [¹⁸F]PSMA-1007 PET/CT: a comparison to MRI using histopathology as reference. *EJNMMI Rep*. 2025 Jan 3;9(1):1.
377. Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrone K, Ayadi M, Beltran H, **Bjartell A**, Blanchard P, Boulton MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono

JS, De Santis M, Duran I, Efsthathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khaulil RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, Türkeri LN, Uemura H, Ürün Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). *Eur Urol.* 2025 Feb;87(2):157-216.

378. Twilt JJ, Saha A, Bosma JS, van Ginneken B, **Bjartell A**, Padhani AR, Bonekamp D, Villeirs G, Salomon G, Giannarini G, Kalpathy-Cramer J, Barentsz J, Maier-Hein KH, Rusu M, Rouvière O, van den Bergh R, Panebianco V, Kasivisvanathan V, Obuchowski NA, Yakar D, Elschot M, Veltman J, Fütterer JJ, Huisman H, de Rooij M; PI-CAI Consortium / list of collaborators. Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study. *Eur Urol.* 2025 Feb;87(2):240-250.

379. Bialas P, Kobayashi T, Hellsten R, Krzyzanowska A, Persson M, Marginean F, Trudel D, Garraway IP, Trock BJ, Taimen P, Saad F, Mirtti T, Knudsen B, De Marzo AM, **Bjartell A**. pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post-Initiation of Androgen Deprivation Therapy. *Prostate.* 2025 Feb;85(3):252-264.

380. Singh D, Carvalho AL, Mosquera I, Vilaseca J, Patasius A, Miksiene G, Tupikowski K, Amorín ÁG, Antelo MT, Quinteiro MC, Galvin D, Sheridan B, Heijnsdijk E, van den Bergh RCN, Roobol MJ, Venderbos LDF, Collen S, van Poppel H, Basu P, Chandran A; **PRAISE-U consortium**. Monitoring of prostate cancer screening in the European Union: development of key performance indicators through the PRAISE-U project. *EClinicalMedicine.* 2025 Jan 23;80:103022.

381. Lantz A, Li Y, Carlsson S, Stranne J, Angenete E, Akre O, Bjartell A, Mansoori M, Ehrencrona C, Wiklund P, Haglund E. Robotic Versus Open Radical Prostatectomy, Differences in Prostate Cancer-specific Survival-12 Years of Follow-up in the LAParoscopic Prostatectomy Robot Open Trial. *Eur Urol Oncol.* 2025 May 23:S2588-9311(25)00127-0. doi: 10.1016/j.euo.2025.05.004. Epub ahead of print. PMID: 40413128.

382. Twilt JJ, Saha A, Bosma JS, Padhani AR, Bonekamp D, Giannarini G, van den Bergh R, Kasivisvanathan V, Obuchowski N, Yakar D, Elschot M, Veltman J, Fütterer J, Huisman H, de Rooij M; PI-CAI Consortium. AI-Assisted vs Unassisted Identification of Prostate Cancer in Magnetic Resonance Images. *JAMA Netw Open.* 2025 Jun 2;8(6):e2515672.

383. Sharifi MN, Feng E, Rydzewski NR, Taylor AK, Sperger JM, Shi Y, Helzer KT, Bootsma ML, Carreno V, Chang AH, Nunamaker LA, Blitzler GC, Shang TA, Subramanian A, **Bjartell A**, Josefsson A, Wikström P, Feng E, Kohli M, Yang R, Dehm SM, Small EJ, Aggarwal R, Quigley DA, Lang JM, Zhao SG, Sjöström M. Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer. *Mol Oncol.* 2025 Aug;19(8):2348-2365.

384. Bangma C, Doan P, Zhu L, Remmers S, Nieboer D, Helleman J, Roobol MJ, Sugimoto M, Chung BH, Lee LS, Frydenberg M, Klotz L, Peacock M, Perry A, **Bjartell A**, Rannikko A, Van Hemelrijck M, Dasgupta P, Moore C, Trock BJ, Pavlovich C, Steyerberg E, Carroll P, Koo KC, Hayen A, Thompson J; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance

(GAP3) Consortium. Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry. *Eur Urol Oncol*. 2025 Apr;8(2):324-337.

385. Örbom A, Evans-Axelsson S, Jansson B, Vilhelmsson Timmermand O, Tran TA, **Bjartell A**, Strand SE. Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody R6.5 in a prostate cancer mouse model. *Nuklearmedizin*. 2025 Apr;64(2):163-169.

386. **Bjartell A**, Krzyzanowska A, Liu VYT, Tierney M, Royce TJ, Sjöström M, Palominos-Rivera MM, Chen E, Kraft A, Esteva A, Feng FY. Validation of a Digital Pathology-Based Multimodal Artificial Intelligence Biomarker in a Prospective, Real-World Prostate Cancer Cohort Treated with Prostatectomy. *Clin Cancer Res*. 2025 Apr 14;31(8):1546-1553.

387. de Vos II, Marengi C, Badenchini F, Boevé ER, Lozano-Uruñuela F, Graefen M, Rannikko AS, Staerman F, Sugimoto M, Kato T, Somford DM, Frydenberg M, Bangma CH, Remmers S, Roobol MJ; Prostate Cancer Research International: **Active Surveillance (PRIAS) consortium**. Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment. *BJU Int*. 2025 Aug;136(2):245-253.

388. Melão BVLA, Assel M, Pere M, Nalavenkata S, Touijer K, Laudone V, Lin DW, Gomez Rivas J, **Bjartell A**, Carlsson SV. Assessment of Discharge Recommendations after Radical Prostatectomy. *Urol Oncol* 2025 Aug;43(8):471.e9-471.e16.

389. Karpinski MJ, Rahbar K, Bögemann M, Nikoukar LR, Schäfers M, Hoberück S, Miederer M, Hölscher T, Rasul S, Mischczyk M, Lanfranchi F, Bauckneht M, Pfob CH, Kind F, Goffin K, Hüsing A, Kesch C, Herrmann K, Stuschke M, Gafita A, Calais J, Hofman MS, Hope TA, Miksch J, Soeterik TFW, Di Giorgio A, Farolfi A, **Bjartell A**, Trägårdh E, Unterrainer LM, Holzgreve A, Sheikh GT, Rauscher I, Eiber M, Hadaschik BA, Fendler WP. Updated prostate cancer risk groups by PSMA-PET PROMISE (PPP2): Results from an international multi-center registry study. *Eur Urol* 2025 May 2:S0302-2838(25)00249-0.

390. Van Renterghem K, De Bruyn H, Yebes A, Calopedos R, Deho F, Torremadé J, D'Anna M, Bettocchi C, Gomez BG, Caris C, Witjes W, Moncada I, Ralph D; EAU Research Foundation **PHOENIX Study Group**. Early complications after penile prosthesis surgery: findings from the PHOENIX multicenter registry. *Int J Impot Res*. 2025 May 7.

391. Ng ABCD, Asif A, Agarwal R, Panebianco V, Girometti R, Ghai S, Gómez-Gómez E, Budäus L, Barrett T, Radtke JP, Kesch C, De Cobelli F, Pham T, Taneja SS, Hu JC, Tewari A, Rodríguez Cabello MÁ, Dias AB, Mynderse LA, Borghi M, Boesen L, Singh P, Renard-Penna R, Leow JJ, Falkenbach F, Pecoraro M, Giannarini G, Perlis N, López-Ruiz D, Kastner C, Schimmöller L, Rossiter M, Nathan A, Khetrpal P, Chan VW, Haider A, Clarke CS, Punwani S, Brew-Graves C, Dickinson L, Mitra A, Brembilla G, Margolis DJA, Takwoingi Y, Emberton M, Allen C, Giganti F, Moore CM, Kasivisvanathan V; **PRIME Study Group Collaborators**. Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial. *JAMA*. 2025 Sep 10:e2513722.

392. Herrmann K, Walz J, MacLennan S, Briganti A, Cornford P, Czernin J, Eiber M, Fanti S, Fendler WP, Fizazi K, Gafita A, Gillessen S, Goffin K, Hadaschik B, Hofman MS, Hope TA, Maurer T, Morgans AK, Morris MJ, Murphy DG, Oprea-Lager DE, Ost P, ÓSullivan JM, Rouvière O, Sandhu S, Sartor O, Sathekge MM, Tempany C, Witjes W, Emmett L, **Bjartell AS**. SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis. *Eur Urol*. 2025 Sep 12:S0302-2838(25)00482-8.

Published reviews (Peer-reviewed)

1. Sundler F, **Bjartell** A, Böttcher G, Ekblad E, Håkanson R. Gastroenterol Clin Biol. 1987;11(3 Pt 2):14B-26B. Localization of enkephalins and other endogenous opioids in the digestive tract.
2. Christensson A, **Bjartell** A, Lilja H. The significance of serpins in the regulation of proteases in the male genital tract. Adv Exp Med Biol. 1997;425:163-76.
3. van Gils MP, Stenman UH, Schalken JA, Schröder FH, Luider TM, Lilja H, **Bjartell** A, Hamdy FC, Pettersson KS, Bischoff R, Takalo H, Nilsson O, Mulders PF, Bangma CH. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol. 2005 Dec;48(6):1031-41.
4. Yossepowitch O, **Bjartell** A, Eastham JA, Graefen M, Guillonneau BD, Karakiewicz PI, Montironi R, Montorsi F. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol. 2009 Jan;55(1):87-99.
5. Seitz M, Shukla-Dave A, **Bjartell** A, Touijer K, Sciarra A, Bastian PJ, Stief C, Hricak H, Graser A. Functional magnetic resonance imaging in prostate cancer. Eur Urol. 2009 Apr;55(4):801-14
6. Bastian PJ, Carter BH, **Bjartell** A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schröder F. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol. 2009 Jun;55(6):1321-30.
7. Tomlins SA, **Bjartell** A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009 Aug;56(2):275-86.
8. Ulmert D, O'Brien MF, **Bjartell** AS, Lilja H. Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol. 2009 Jul;6(7):384-91.
9. Murphy DG, **Bjartell** A, Ficarra V, Graefen M, Haese A, Montironi R, Montorsi F, Moul JW, Novara G, Sauter G, Sulser T, van der Poel H. Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol. 2010 May;57(5):735-46.
10. Catto JW, Alcaraz A, **Bjartell** AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011 May;59(5):671-81.
11. Sciarra A, Barentsz J, **Bjartell** A, Eastham J, Hricak H, Panebianco V, Witjes JA. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol. 2011 Jun;59(6):962-77.
12. Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, **Bjartell** AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol. 2011 Aug;60(2):291-303.
13. Montironi R, Egevad L, **Bjartell** A, Berney DM. Role of histopathology and molecular markers in the active surveillance of prostate cancer. Acta Oncol. 2011 Jun;50 Suppl 1:56-60.
14. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, **Bjartell** A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol. 2011 Jun;50 Suppl 1(Suppl 1):61-75.

15. **Bjartell A**, Montironi R, Berney DM, Egevad L. Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. *Acta Oncol.* 2011 Jun;50 Suppl 1:76-84.
16. Roobol MJ, Haese A, **Bjartell A**. Tumour markers in prostate cancer III: biomarkers in urine. *Acta Oncol.* 2011 Jun;50 Suppl 1:85-9.
17. Jerónimo C, Bastian PJ, **Bjartell A**, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, Shariat SF. Epigenetics in prostate cancer: biologic and clinical relevance. *Eur Urol.* 2011 Oct;60(4):753-66.
18. Auprich M, **Bjartell A**, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. *Eur Urol.* 2011 Nov;60(5):1045-54.
19. Fine SW, Amin MB, Berney DM, **Bjartell A**, Egevad L, Epstein JI, Humphrey PA, Magi-Galluzzi C, Montironi R, Stief C. A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens. *Eur Urol.* 2012 Jul;62(1):20-39.
20. Trinh Q-D, **Bjartell A**, Freedland SJ, Hollenbeck BK, Hu JC, Shariat SF, Sun M, Vickers AJ. A systematic review of the volume-outcome relationship for radical prostatectomy. *Eur Urol.* 64(5):786-98, 2013
21. Barbieri CE, Bangma CH, **Bjartell A**, Catto W, Culig Z, Grönberg H, Luo J, Visakorpi T, Rubin MA. The mutational landscape of prostate cancer. *Eur Urol.* 64(4):567-76, 2013.
22. Boström PJ, **Bjartell AS**, Catto JMF, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, Cooperberg MR. Genomic predictors of outcome in prostate cancer, *Eur Urol* 2015 Dec;68(6):1033-44.
23. Evans-Axelsson S, Timmermand OV, **Bjartell A**, Strand SE, Elgqvist J. Radioimmunotherapy for Prostate Cancer-Current Status and Future Possibilities. *Semin Nucl Med.* 2016 Mar;46(2):165-79.
24. Ceder Y, **Bjartell A**, Culig Z, Rubin MA, Tomlins SA, Visakorpi T. The Molecular Evolution of Castration Resistant Prostate Cancer. *Eur Urol Focus* 2016 Dec;2(5):506-513
25. Bruinsma SM, Roobol MJ, Carroll PR, Klotz L, Pickles T, Moore CM, Gnanapragasam VJ, Villers A, Rannikko A, Valdagni R, Frydenberg M, Kakehi Y, Filson CP, Bangma CH; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (**GAP3**) consortium. Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure. *Nat Rev Urol.* 2017 May;14(5):312-322.
26. Smith EJ, MacLennan S, **Bjartell A**, Briganti A, Knoll T, Loch T, Ribal MJ, Sylvester R, Van Poppel H, N'Dow J. Ensuring Consistent European-Wide Urological Care by the Use of Evidence-Based Clinical Practice Guidelines: Can We Do Better. *Biomed Hub.* 2017 Nov 21;2(Suppl 1):162-168.
27. Lam TBL, MacLennan S, Willemse PM, Mason MD, Plass K, Shepherd R, Baanders R, Bangma CH, **Bjartell A**, Bossi A, Briers E, Briganti A, Buddingh KT, Catto JWF, Coecchia M, Cox BW, Cumberbatch MG, Davies J, Davis NF, De Santis M, Dell'Oglio P, Deschamps A, Donaldson JF, Egawa S, Fankhauser CD, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Gross T, Grummet JP, Henry AM, Ingels A, Irani J, Lardas M, Liew M, Lin DW, Moris L, Omar MI, Pang KH, Paterson CC, Renard-Penna R, Ribal MJ, Roobol MJ, Rouprêt M, Rouvière O, Sancho Pardo G, Richenberg J, Schoots IG, Sedelaar JPM, Stricker P, Tilki D, Vahr Lauridsen S, van den Bergh RCN,

Van den Broeck T, van der Kwast TH, van der Poel HG, van Leenders GJLH, Varma M, Violette PD, Wallis CJD, Wiegel T, Wilkinson K, Zattoni F, N'Dow JMO, Van Poppel H, Cornford P, Mottet N. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). *Eur Urol.* 2019 Dec;76(6):790-813.

28.Omar MI, Roobol MJ, Ribal MJ, Abbott T, Agapow PM, Araujo S, Asiimwe A, Auffray C, Balaur I, Bayer K, Bernini C, **Bjartell A**, Briganti A, Butler-Ransohoff JR, Campi R, Cavelaars M, De Meulder B, Devecseri Z, Dietrich Voss M, Dimitropoulos K, Evans-Axelsson S, Franks B, Fullwood L, Horgan D, Jane Smith E, Kiran A, Kivinummi K, Lambrecht M, Lancet D, Lindgren P, MacLennan S, MacLennan S, Nogueira M, Moen F, Moinat M, Papineni K, Reich C, Reiche K, Rogiers S, Sartini C, van Bochove K, van Diggelen F, Van Hemelrijck M, Van Poppel H, Zong J, N'Dow J and PIONEER Consortium. Introducing PIONEER: a project to harness big data in prostate cancer research. *Nature Rev Urol. Nat Rev Urol.* 2020 Jun;17(6):351-362.

29.Canesin G, Krzyzanowska A, Hellsten R, **Bjartell A**. Cytokines and JAK/STAT signaling in prostate cancer: overview and therapeutic opportunities. *Current Opinion in Endocrine and Metabolic Research.* 2020; 10: 36-42

30.Beyer K, Moris L, Lardas M, Haire A, Barletta F, Scuderi S, Vradi E, Gandaglia G, Omar MI, MacLennan S, Zong J, Farahmand B, MacLennan SJ, Devecseri Z, Asiimwe A, Collette L, **Bjartell A**, Ndow J, Briganti A, Van Hemelrijck M; PIONEER Consortium. Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. *BMJ Open.* 2021 Feb 11;11(2):e040531..

31.Gonzalez D, Mateo J, Stenzinger A, Rojo F, Shiller M, Wyatt AW, Penault-Llorca F, Gomella LG, Eeles R, **Bjartell A**. Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. *J Pathol Clin Res.* 2021 Feb 25.

32.Zheng J, Sampurno F, George DJ, Morgans AK, Nguyen H, Abraham JL, **Bjartell A**, Davis ID, Fitch MI, Gillessen S, Kanesvaran R, Matthew A, Millar JL, O'Sullivan JM, Payne H, Pouliot F, Yates P, Evans SM. Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. *Clin Genitourin Cancer.* 2022 Apr;20(2):e151-e157.

33.Siltari A, Lönnerbro R, Pang K, Shiranov K, Asiimwe A, Evans-Axelsson S, Franks B, Kiran A, Murtola TJ, Schalken J, Steinbeisser C, **Bjartell A**, Auvinen A; PIONEER Consortium. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis. *Clin Genitourin Cancer.* 2023 Apr;21(2):316.e1-316.e11.

34.Omar MI, MacLennan S, Ribal MJ, Roobol MJ, Dimitropoulos K, van den Broeck T, MacLennan SJ, Axelsson SE, Gandaglia G, Willemse PP, Mastris K, Ransohoff JB, Devecseri Z, Abbott T, De Meulder B, **Bjartell A**, Asiimwe A, N'Dow J; PIONEER Consortium. Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium. *Nat Rev Urol.* 2023 Aug;20(8):494-501.

35. Beyer K, Leenen R, Venderbos LDF, Helleman J, Denijs F, Bramer W, Vasilyeva V, Briers E, Rivas JG, Chloupkova R, Majek O, Annemans L, Vynckier P, Basu P, Chandran A, van den Bergh R, Collen S, van Poppel H, Roobol MJ; The PRAISE-U Consortium. Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: **PRAISE-U Consortium.** *J Pers Med.* 2024 Jan 11;14(1):84.

36.Lawlor A, Lin C, Gómez Rivas J, Ibáñez L, Abad López P, Willemse PP, Imran Omar M, Remmers S, Cornford P, Rajwa P, Nicoletti R, Gandaglia G, Yuen-Chun Teoh J, Moreno Sierra J,

Golozar A, **Bjartell A**, Evans-Axelsson S, N'Dow J, Zong J, Ribal MJ, Roobol MJ, Van Hemelrijck M, Beyer K; PIONEER Consortium. Predictive Models for Assessing Patients' Response to Treatment in Metastatic Prostate Cancer: A Systematic Review. *Eur Urol Open Sci* 2024 Apr 4;63:126-135.

37. Schostak M, Bradbury A, Briganti A, Gonzalez D, Gomella L, Mateo J, Penault-Llorca F, Stenzinger A, Wyatt AW, **Bjartell A**. Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer. *Eur Urol Oncol.* 2024 Jun;7(3):344-354

38. Vynckier P, Annemans L, Raes S, Amrouch C, Lindgren P, Májek O, Beyer K, Leenen RCA, Venderbos LDF, Denijs F, van Harten MJ, Helleman J, Chloupková R, Briers E, Vasilyeva V, Rivas JG, Basu P, Chandran A, van den Bergh RCN, Collen S, Van Poppel H, Roobol MJ; Members of the **PRAISE-U Consortium**. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe. *Eur Urol.* 2024 Nov;86(5):400-408..

39. Sakalis V, Bhattacharya Y, Beyer K, Murray C, Smith EJ, Willemse PM, Gandaglia G, Boissier R, Borkowetz A, Dabestani S, Leenen RCA, Vilaseca A, Maresca G, Teoh J, Gómez Rivas J, Rajwa P, Lardas M, Grivas N, Van den Broeck T, Pradere B, Schouten N, Tandogdu Z, Evans-Axelsson S, Maclennan S, Thomas M, Briganti A, **Bjartell A**, Cornford P, Kruger H, N'Dow J, Roobol MJ, Omar MI; OPTIMA Consortium. AGREE II Quality Assessment of National and International Clinical Practice Guidelines on Prostate Cancer Management by the OPTIMA Consortium. *Eur Urol Open Sci.* 2024 Nov 12;70:183-193

40. Lawlor A, Beyer K, Russell B, Steinbeisser C, **Bjartell A**, De Meulder B, Omar MI, Hulsen T, Butler J, N'Dow J, Rivas JG, Gandaglia G, Nicoletti R, Sakalis V, Smith EJ, Maass M, Zong J, Fullwood L, Abbott T, Tafreshiha A, Papineni K, Snijder R, Horgan D, Seager S, Evans-Axelsson S, Ribal MJ, Roobol MJ, Van Hemelrijck M; PIONEER Consortium. PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research. *Nat Rev Urol.* 2025 Feb;22(2):116-124.

41. Lin PH, Burwell AD, Giovannucci EL, Loeb S, Chan JM, Tuttle B, Nunzio C, **Bjartell A**, Aronson W, Freedland SJ. Dietary Patterns in Prostate Cancer Prevention and Management: A Systematic Review of Prospective Cohort Studies and Randomized Clinical Trials. *Eur Urol.* 2025 Aug 19:S0302-2838(25)00433-6.

Other papers

Bjartell A and Ulmert D. Chapter 6.6 Clinical Features, Assessment, and Imaging of Prostate Cancer. Pp 493-500. Oxford Textbook of Urological Surgery. First Edition 2017. Eds Freddie C Hamdy and Ian Eardley. ISBN 978-0-19-965957-9

Bjartell A and DeSantis M (Eds.) Chapter 11. Cytotoxic Chemotherapy and Targeted Agents. International Consultation on Medical Treatment of Urological Malignancies Lisbon 2014. (Eds. C Stief, K Fizazi, C Evans. Published by EAU and ICUD 2015. ISBN: 9789079754823

Bjartell A. Re: Activity and Safety of ODM-201 in Patients with Progressive Metastatic Castration-resistant Prostate Cancer (ARADES): An Open-label Phase 1 Dose-escalation and Randomised Phase 2 Dose Expansion Trial. *Eur Urol.* 2015 Feb;67(2):348-9.

Anand AU, **Bjartell A**. Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate

Cancer. Eur Urol. 2015 Feb;67(2):349-50.

Bjartell AS. Making Predictive Biomarkers Readily Available. *Eur Urol.* 2016 Oct;70(4):609-610.

Bjartell AS. Re: The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. *Eur Urol.* 2016 Oct;70(4):700.

Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer.
Sjöström M, **Bjartell A.** *Eur Urol.* 2023 Oct;84(4):437-438.

Carlsson SV, Lilja H, Vickers AJ, **Bjartell AS.** Re: Early Prostate Cancer Deaths Among Men with Higher vs Lower Genetic Risk. *Eur Urol.* 2025 Mar;87(3):368-369.

Projects

Translational and clinical studies on prostate cancer

Memberships

1987	Swedish Medical Association (SLS)
1994	International Society of Urological Pathology (ISUP)
1996	European Association of Urology (EAU)
1996	Nordic Association for Andrology (NAFA)
1997	Swedish Urological Association (SUF)
1998	American Society of Andrology (ASA)
2002	American Urological Association (AUA)
2003	Association for Academic Urologists in Europe (AAEU)
2014	American Society for Oncology (ASCO)

Other Relevant Information